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INTRODUCTION TO THE EVALUATION REPORT 
AND 
GUIDE TO THE ANNEXES 
Introduction 
This report is presented in two volumes. The first volume contains the Executive 
Summary and the Principal Recommendations. Part 1 is designed for people who want 
to assimilate the main results of the review and is presented in this slim document for 
the benefit of those who are already overburdened with paper. 
The Executive Summary gives, in five pages, the main findings and conclusions of the 
review conducted by the Panel. The Pricipal Recommendations comprise one page of 
the seven main recommendations derived from the Executive Summary. Subsidiary 
recommendations are given at the end of some of the sections in the Annexes. 
Part 2 gives full details of the main work of the evaluation in a series of Annexes. The 
remainder of this chapter is a guide to those Annexes. 
Annex I Programme Description 
This Annex gives a description of the BRIDGE Programme, its budget and its 
relationship to preceding Biotechnology programmes. It indicates the areas covered by 
the programme, their expenditures and the history of its main events. 
Annex Π Methodology 
Annex II and its sub-annexes describe the methods that the Panel used to conduct the 
review. It indicates the main groups of people that were interviewed, the projects areas 
that were selected for interview and the main topics that were discussed with 
interviewees. It also describes the use of the questionnaires that were devised to gather 
information from Participants and others. 
Annex DT Evaluation of the Project Selection Process 
This Annex and its sub-annexes present the Panel's views on the project selection 
process, which has been one of the most criticised elements of the Programme in the 
interviews that were conducted. The main Annex is a narrative evaluation with 
recommendations for improvement, some of which are repeated in the Executive 
Summary. The sub-annexes consist of a more detailed analysis of the process with 
representative documents, figures and a typical evaluation. Information from the Project 
Managers is included by way of further clarification. 
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Annex IV Evaluation of Projects by Programme Area 
This Annex reports the evaluation of projects grouped by Programme Area. The 
evaluation was based on the published project reports, publications from the 
Commission, a brief analysis of the publication record attached to these reports together 
with relevant information from the questionnaires and discussions at interview with 
selected participants and non-participants. 
Annex V Impact of the Programme on the EU Biotechnology Industry 
Since one of the main objectives of the EU R&D Programmes is to improve the 
competitiveness of EU industry, the Panel has canvassed the views of industry 
concerning the Programme. These views were obtained from discussions at interview 
and from the findings of a small questionnaire survey addressed mainly to industrialists 
whose companies had not participated in the Programme. Annex V presents these views 
and an assessment of the impact of the Programme on the EU Biotechnology industry 
in general. 
Annex VI Main findings of the Questionnaire Surveys 
This Annex highlights the main conclusions that can be drawn from the responses to the 
questionnaires that the Panel sent to Project Co-ordinators and Partners. The sub-
annexes include the questionnaires with the summation of the responses received in each 
case. 
Annex Vu Evaluation of Programme Management. 
The trans-national, multi-party, collaborative nature of the projects within the 
Programme produces a need for careful, sensitive and professional management at a 
number of levels. This Annex presents an evaluation of both the scientific and 
administrative management of the Programme provided by the Biotechnology Unit of 
DG XII. Some comments on the scientific management provided by the project co-
ordinators are given in Annex VI. 
Annex VIH Evaluation of the Training Activities 
Training has been recognised as an important element of earlier Biotechnology 
Programmes. Evaluation of those programmes included specific recommendations for 
the future support of training activities. The Panel has therefore spent a significant 
proportion of its time considering these activities. The BRIDGE Training Programmes 
have been analysed in the context of the Programmes that preceded and those that 
followed. This evaluation is the subject of Annex VIII. 
Annex IX Evaluation of Concertation Actions 
Concertation was identified as an important aspect of the early Biotechnology 
Programmes. It was also included as an important function of BRIDGE, but during the 
Programme, the mechanism for taking Concertation actions was changed. Annex IX 
presents the result of the evaluation of this activity and makes suggestions for the main 
focus of Concertation actions in the future. 
Annex X A Survey of R&D spending by National Governments and the EU 
During its deliberations, the Panel frequently came up against the question of the 
importance of EU funding of Biotechnology compared to that of the National 
Goverments. The Panel obtained the views of a number of groups on this question. One 
of the important pieces of evidence when considering what the proportion of spending 
by the EU or the National Governments should be, is the knowledge of what it is now 
and has been in the past. The figures that are presented in Annex X were obtained and 
calculated by the Panel and have informed the discusion on this and related issues. 
Annex XI Evaluation of the relationship of COST actions to BRIDGE 
COST, as probably the earliest paradigm of trans-national scientific collaboration, has 
made an important contribution to the development of other Programmes. Annex XI 
presents an evaluation of its relationship to BRIDGE. 
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EXECUTIVE SUMMARY 
1. BRIDGE and the European Scientific Community 
One of the most noticeable impacts of the BRIDGE Programme is the continued 
development of a truly transnational scientific community in European biotechnology, 
the beginnings of which were apparent in the earlier BEP and BAP programmes. 
Transnational collaborations are seen to be mainly positive and a good way to expand 
the effectiveness of national resources. 
We could find no evidence to support the belief that the participation of laboratories 
from different countries is often at the expense of the overall scientific quality and 
productivity of projects. It is recognised that transnational projects are a good way of 
spreading expertise to scientifically less favoured regions. Perhaps for this reason some 
projects included participants that would not, in isolation, have achieved fundable ratings 
for their contributions. We are convinced that the scientific standards of projects did not 
suffer as a result of this inclusion but obviously close attention must be paid to the 
overall quality of proposals to ensure that high quality is spread rather than eroded by 
this mechanism. 
We conclude that, along with the transnational component of the projects, the training 
programmes, exchanges of personnel and project meetings all contribute to fostering the 
development of a community spirit that is open to wider international developments, 
more open to industry and its scientists and able to overcome the limitations of 
nationalistic approaches. 
2. Training 
Training of young scientists in countries other than their own is particularly important 
in developing the community. It is also important in ensuring a supply of talented 
scientists for industry, (see section 3 of this summary). The training aspects of the 
programme should therefore be developed. Short term (3 month) fellowships would 
greatly facilitate transfer of skills between laboratories. A system of such fellowships 
should be devised and introduced. We have seen evidence that the publication criteria 
used in the selection of fellows are excluding talented young people in the early phase 
of their careers. New PhD's who have just completed a thesis rarely have many 
publications. We add our voice to those of previous Review Panels who have requested 
that the training budget be increased to 15 % of the expenditure and that the number of 
fellowships be increased. This has not yet been achieved. 
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3. The involvement of Industry 
Industry played a central role in the design of the Programme and the selection of the 
target areas and participated directly in 10% of the BRIDGE projects. This involvement 
was not equally distributed in Europe. A number of indicators show that interactions 
were best developed in the Netherlands and the United Kingdom, rather less developed 
in France and Germany and were sporadic in other European countries. This pattern is 
still seen today, although project participants were often optimistic about post BRIDGE 
activities with industry. Many developed links with industry as a result of being involved 
in a BRIDGE project and felt that their opportunities for future industrial collaboration 
were increased while not impairing access to National funding. 
Since only 10% of the projects involved direct industrial participation, it is clear that a 
very large number of potentially eligible industries did not participate. The Panel 
therefore conducted a limited and informal survey of 37 leaders of European 
biotechnology industries thoughout Europe to determine how they valued European and 
National biotechnology programmes. The general feeling is that European programmes 
are indirectly important to their industries by creating a European scientific community. 
Industry did not regard these programmes as the right place to access specific results 
such as patentable knowledge nor have they been designed to support new industrial 
appoaches and strategies. National biotechnology programmes were seen as somewhat 
more appropriate for this latter purpose. Despite this perception of the indirect relevance 
of National and European biotechnology programmes, virtually all felt that both National 
and European funding should be expanded and that at least 20% of the available 
government funds for biotechnology should be distributed via European programmes. 
Industrialists have made it clear that they do not wish to see academic laboratories 
attempting to do the job of industrial laboratories in developing new products and 
processes. Industry needs access to experts who are at the forefront of advances in basic 
science and to a stream of highly trained, talented and skilled young scientists. 
We therefore conclude the best way to increase industrial competitiveness is first, to 
identify the needs of industry and the bottlenecks that impede its progress and to give 
priority to fundamental research projects that address these areas and second to intensify 
the development of training programmes. There is also evidence that Industrial Platforms 
generate valuable interactions and can therefore help to improve industrial access to 
academic research. In these circumstances, we believe that industrial participation at 
10% of the contractors is more than adequate to confirm the industrial relevance of the 
Programme. 
4. European and National Scientific Programmes. 
There is clear evidence of an interaction between National and EU programmes. The 
Bridge Programme has succeeded in identifying and supporting key areas in 
Biotechnology research and has thus played an important role in complementing National 
research programmes. Most respondents agree that there is complementarity between the 
objectives of these sources of research support, although it appears that some National 
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programmes tend to reflect the European objectives. 
The overlap between the scientific goals of the European and National programmes has 
led to confusion about their relative objectives and contributions. National civil servants 
have recently been referring fund-seeking scientists to Europe on the grounds that 
National governments contribute increasingly to European programmes and that such 
funds should be repatriated as efficiently as possible. 
The BRIDGE Programme represented about 2% of the total National funding for 
biotechnology. In the FPIII Biotech Programme this had increased to about 3.5% and 
for FPrV it will amount to about 10%, based on data extracted from the European 
Report on Science and Technology indicators 19941 as described in Annex X. These 
numbers show that the European contribution has brought added value mainly through 
co-ordination and networking and not by massive funding. 
The 10% of total biotechnology funding that will be disbursed through FPIV will be 
quite acceptable to most participants of the BRIDGE Programme. At least half felt that 
EU funding should be increased to more than 20% of the total. The wishes of the 
scientists who did not participate in BRIDGE are unknown; it is unlikely that they would 
favour such high percentages. However, our informal survey of 37 industrial leaders, 
mentioned above, most from companies that did not participate in BRIDGE, showed that 
32 favoured spending more than 20% of government funds for biotechnology research 
in Europe via EU programmes, without lowering National funding. Only one favoured 
increasing European funding at the expense of National funding. 
The panel concludes from this information that the European programmes in 
biotechnology are admirably meeting the needs of academic researchers and industry 
alike by steadily increasing the support of biotechnology R&D and that there is scope 
for further increase in the EU contribution. 
We have observed that there is strong emphasis made by DG XII staff and committees 
on the need for direct industrial participation in European biotechnology programmes. 
This is based on the perception that such participation is necessary for the development 
of a strong and competitive biotechnology industry. As a result, current Call for 
Proposals are highly prescriptive and leave little room for flexibility. Our evaluation 
indicates that this concern may be misplaced. As mentioned above, the major effect of 
the programmes appear to be indirect. They do not, on the whole, solve specific 
problems in product or process development nor do they lead to strong patent positions. 
Instead, they bring together European researchers who formerly operated in relative 
isolation. 
'Report EUR 15897 EN, October 1994 produced by the EC, DGXII 
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This is in accord with the view, shared by most of the surveyed industry leaders, that 
basic (curiosity driven) research is an important source of progress and new ideas in 
biotechnology. There is support for basic science at the National level but as the EU 
programmes continue to expand it will be necessary to ensure that funding of basic 
science in Europe remains at a level necessary for the development of a competitive 
biotechnology industry. This is likely to require flexibility in programme design. A 
relaxation of the present prescriptive system would be in accord with the stated wishes 
of industry in preferring to see academics concentrating on leading-edge science, thereby 
supporting industrial competitiveness. 
5. Project evaluation and selection procedure 
There is considerable criticism from the scientific community and a number of national 
agencies concerning the process of project evaluation and selection. We conclude that 
the process suffers from a lack of transparency, inadequate feedback particularly to 
unsuccessful applicants and some misunderstanding about the use of the term "peer 
review" that is more than merely semantic. 
We are aware that Panels reviewing other programmes have reached the same 
conclusion but that there have been no changes in the process partly because it is used 
across all EU programmes. However, this topic is so important that the Panel made a 
special study that is reported in a later chapter. This analysis led to a number of specific 
recommendations that are reported in detail in that chapter and repeated in abbreviated 
form in the Principal Recommendations. 
In our view the Framework Programmes are now sufficiently large that it is not 
necessary that they are all administered in an identical way. We believe that it will 
improve the standing of the European Programmes if careful note is taken of our 
recommendations that the total time of the award process should be shortened, that the 
system should be more transparent and that feedback should be improved. 
6. Interdependence and collaboration of Partner laboratories 
The aim of developing a European scientific community will be served more effectively 
if projects demonstrate real interdependence between contracting laboratories. This may 
result from a need for interdisciplinary work but interdisciplinarity is not an essential 
component of interdependence. However, we observed that some projects seemed to 
comprise a collection of independent pieces of work held together only by their 
relationship to the field. It is also apparent that many projects resulted in only a few 
joint publications which are key indicators of true co-operation and partnership. One aim 
of the selection process is to choose projects that involve true interdependence. It is 
possible that this indicator is more difficult to assess than it might appear or perhaps it 
is sometimes less important than other considerations. We feel that the methods of 
assessing this indicator and the weighting it receives should be reviewed to ensure the 
interdependence of the contributions of all partners to a project. 
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7. Management and administration 
The administration and management of the programme has been the subject of mixed 
reports in various respects. 
The Programme Managers have received approving comments from a number of 
quarters and we agree that they are competent, professional and enthusiastic. 
Furthermore, criticisms of excessive bureaucracy do not apply to the administration of 
the financial management of projects once awarded. Indeed, DG XII showed admirable 
flexibility in the disposition of funds to achieve project objectives. 
However, there are three areas where we observe that bureaucratic procedures hinder 
effective management of the process and execution of the science. First, a significant 
minority even of successful applicants found the documents in the Call for Proposals 
complex, obscure and full of Commission jargon. Second, the inter-service review of 
proposals is unreasonably long in view of the tight deadlines imposed on the proposers. 
Third, the procedures of contract negotiation, once projects have received scientific 
approval, are complex, bureaucratic and drawn out. They compare poorly with similar 
procedures at the National level and are thus a source of great frustration even to 
successful applicants. 
Our surveys show that, in a rapidly advancing field, the delays in starting projects that 
result from these deficiencies have a serious detrimental effect on scientific progress and 
international competitiveness, reducing the value of the research to industry. Thus some 
of the bureaucratic procedures of the Commission are frustrating the Council's aim of 
improving industrial competitiveness and they have also been given to us as reasons for 
the non-participation of some industrial laboratories in the programme. 
8. Quality of the Programme output 
Overall, the quality of the work resulting from the Programme was high and the 
publication record is creditable. Of course a few projects did not fulfil, or had over-
ambitious objectives and some had a poor publication output. We conclude that the 
objective of supporting high quality science has been met and that the impact of the 
successful projects far outweighs that of the few that were less successful. 
9. Concertation 
Most of the people we interviewed feel that the concertation activities of Biotechnology 
programmes need to be fully co-ordinated and integrated across all the fields of 
application of Biotechnology, because many of the aspects of concertation are similar 
across a number of industrial sectors. These activities were formerly the responsibility 
of CUBE. 
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Within the overall concertation activity the Panel has observed a strong need for 
particular attention to be paid to methods of proactively informing certain audiences, 
such as Members of the European Parliament, public bodies and pressure groups. It is 
not easy to make good judgements when accurate information is lacking. New methods 
of easy information transfer should be explored, appropriate to the groups being 
addressed. Methods of achieving this have not been successful in the past and new 
methods should be considered. 
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PRINCIPAL RECOMMENDATIONS 
1. We recommend that the fostering of a European scientific community should continue 
to be a major objective of future Programmes. 
2. We recommend that there should be no explicit or implicit requirement for industry 
participation in specific projects. The development of a European scientific community 
and the promotion of industrial competitiveness does not require such participation, 
provided that industry continues to be actively involved in the design of Programmes. 
Our analysis shows that industry is highly interested in Biotechnology Programmes 
despite the fact that it is generally not able to profit directly from such Programmes. 
Instead industry profits from indirect effects and therefore supports further increases in 
Programme funding. 
3. We recommend that the training aspects of the future programmes should be 
expanded and developed. We recommend that 15% of the budget be allocated to 
training; that the number of fellowships be increased; that a system of short term, (three 
month) fellowships be developed; that the publication criteria for selection of fellows be 
revised to permit the entry of new PhD's whose thesis work is not yet published in full. 
4. Our findings show that the project selection procedure needs to be revised to make 
it quicker, more transparent and to provide better feedback, particularly to unsuccessful 
applicants. We recommend: that reviewers are sent copies of the projects they are to 
review two to three weeks before the meetings; that applicants are given a one page 
analysis and critique of their applications; that the total list of reviewers from which 
individual review panels are drawn be published, if necessary after the process is 
complete. Anonymity of reviewers must continue to be protected. More detailed 
recommendations and the analysis on which they are based are given in a later chapter 
of the Report. 
5. We have observed that internal Commission procedures, such as the inter-service 
review, contribute substantially to the wasteful delays that diminish the competitiveness 
of the output of programmes. We recommend that these procedures be revised. We also 
recommend that the time taken for contract negotiation be shortened. This can be 
achieved by simplifying and streamlining the procedure. 
6. We have found that some projects were not truly collaborative. We therefore 
recommend that the evaluation procedure put more emphasis on the requirement for 
interdependence of the contributions of individual project participants and less on the 
requirement for interdisciplinarity. 
7. We recommend that particular attention be paid to methods of informing certain 
audiences, such as Members of the European Parliament, public bodies and pressure 
groups. New proactive mechanisms should be devised. Particular attention should be 
paid to informing these groups about scientific regulatory matters and their social impact 
and about intellectual property matters relating to biotechnology. 
XIX 

Commission of the European Communities 
Evaluation of the Programme for 
Biotechnology Research, Innovation, Development and Growth 
in Europe, (BRIDGE) 
1990-1994 
PART 2 

Annex I 
Programme Description 
Introduction 
The BRIDGE programme (acronym for Biotechnology Research, Innovation, 
Development and Growth in Europe) covered EU supported biotechnology-related 
activities over the four years between 1990-1994. It was the direct successor of two 
earlier programmes specifically designed to reinforce the scientific and technological 
basis of agriculture, industry, healthcare and environmental protection in Europe. These 
were the Biomolecular Engineering Programme (BEP) from 1982-1986, and the 
Biotechnology Action Programme (BAP) from 1985-1989. A dramatic increase in budget 
allocation is indicative of the commitment of the EU to Biotechnology. BEP supported 
91 training contracts and 103 shared-cost research contracts with public and private 
laboratories with a budget of 15 MECU. BAP included 376 laboratories with a budget 
of 75 MECU. In the framework of the BRIDGE programme 100 MECU supported 579 
laboratories throughout Europe, engaged in high quality research in the following fields: 
N-Projects 
Area A: Information infrastructure 
Processing and analysis of biotechnological data (3.9 MECU) 
Culture collections (0.9 MECU) 
Area B: Enabling technologies 
Protein design/molecular modelling 
( 3.3 MECU) 
Biotransformation (3.8 MECU) 
DNA sequencing (0.5 MECU) 
Area C: Cellular Biology 
Physiology and molecular genetics of industrial microorganisms (5.1 MECU) 
Basic biotechnology of plants and associated microorganisms (9.5 MECU) 
Biotechnology of animal cells (7.8 MECU) 
Area D: Pre-Normative Research 
In vitro evaluation of the toxicity of pharmacological activity of molecules (4.5 MECU) 
Biosafety (6.5 MECU) 
T-Projects 
* Sequencing of the Yeast Genome (5.1 MECU) 
* Molecular identification of new plant genes (3.0 MECU) 
* Lipases (4.3 MECU) 
* Lactic acid bacteria (4.9 MECU) 
* High resolution automated microbial identification (HRAMI) (2.1 MECU) 
* Animal cell biotechnology (2.5 MECU) 
* Plant regeneration (3.9 MECU) 
The four areas (Α-D) comprise N-projects, including on average 5-6 laboratories from 
3-4 different member States. The aim of these projects was to remove gaps in 
knowledge and know-how through complementary approaches. The remaining areas 
were addressed by T-projects, which were much larger in terms of participating 
laboratories. These were targeted towards the elimination of specific bottlenecks 
resulting from structural or scale constraints. On average 30 laboratories and 100 staff 
researchers from all over Europe participated in these projects. T-projects were very 
complex in management structure and interactions amongst the participants. A 
monitoring unit with representatives of contractors, programme committee 
"CAN-BRIDGE" (Committee of Advisory Nature) and the Commission was attached to 
each of the T-projects. Reasons for this included to aid in the implementation of the 
programmes and to facilitate communication both internally, within the project, and 
externally with industrial platforms and other entities within the EU. 
Three successive calls for proposals in 1989 and 1990, resulted in the launching of 69 
N-projects and 7 T-projects, encompassing 387 and 192 participating organizations for 
N- and T- projects, respectively. Eleven member states and 5 EFTA countries were 
represented. The table below gives a summary of the selection results. Some of the 
figures are different from those given above due to the inclusion of Concerted Actions 
BRIDGE calls for proposals/funding 
Entire call 
projects selected 
Projects funded 
Proposals 
461 
112 
91 
Partners 
2189 
581 
579 
Funds requested 
MECU 
596 
164 
Funds allocated 
MECU 
430 
114 
70 
DGXII has gone to considerable lengths to ensure that the needs of industry received 
strong priority in the selection of the Programme areas within the framework of 
precompetitive research. In addition, in the project selection phase, the policy was to 
favour the selection of projects that had a direct industrial participation, other things 
being equal. 
Annex Π 
Methodology of the Evaluation Process 
This chapter delineates the methodology, procedures and criteria that the Panel used to 
evaluate the BRIDGE Programme. Our terms of reference are listed in Sub-annex Ha 
and the composition of the evaluation panel is shown in Sub-annex lib 
The panel was assembled in accordance with Council decision of 9 December 1989 
(Official Journal L360/32), and met in Brussels on seven occasions between December 
22, 1994 and July 11th, 1995. Following extensive in depth discussions the Panel 
decided against holding any meetings outside Brussels in order to make better use of 
available resources. All members were familiar with laboratory facilities and unless 
there was something special to see, it was felt preferable to organize discussions at the 
main meetings. The Panel felt initially that some interviews could be conducted with 2-3 
of their members, but the value of the joint experience and the elimination of the need 
to report back, convinced the Panel that wherever possible meetings should take place 
with all members present. 
The major instruments for the evaluation methodology were a series of questionnaires 
and of personal interviews. The questionnaires were addressed to participants, 
coordinators and industrial biotechnology leaders from non-participating compames. The 
interviews involved coordinators, participants and industrialists (participating and 
non-participating); DGXII programme managers; Members of the CAN-BRIDGE; 
Members of the European parliament; Mr. de Nettancourt, former head of 
Biotechnology, Mr. van Hoeck, former Director of Life Sciences, and Mr. Cantley, the 
former head of CUBE; National experts in science policy related to biotechnology; Dr. 
Ganguly, the Chairman of IRDAC; representatives of other Commission Services, 
namely Mr. Gitzinger of VALUE, Mr. Sourmelis, formerly responsible for DGXII 
relations with the European Parliament and Mme Soares, Head of Administration of 
DGXII Life Sciences. 
Individuals to be interviewed from the project teams were selected according to the 
following procedures. Four N-Programme areas and 2-T projects were selected. Panel 
members with primary drafting responsibilities for these areas proposed names of 
individuals to be invited to interview. For each area, 10 names were selected, i.e. 4 
participants, academic or industrial, 2 industrial non-participants, 4 reserves in any of 
these categories. The panel thus hoped to meet the target of 24 participants and 12 
non-participant industrial interviewees. The participants could be either coordinators or 
partners. 
The project areas selected were: 
N-projects- Information databases T-Projects- Lactic acid bacteria 
Biotransformation Arabidopsis 
Biosafety 
Animal Cells 
The Evaluation Unit wrote to the Biotechnology Regulatory Committee comprising the 
12 countries constituting CAN-BRIDGE asking them each to nominate one person to 
attend the third meeting of the Panel. The Evaluation Unit, following requests from the 
Panel, consulted with appropriate Bodies to ascertain which MEPs from among those 
interested in Biotechnology could be interviewed. Panel members nominated National 
experts in science policy related to biotechnology. The Evaluation Unit in consultation 
with the Panel, issued invitations to these individuals. The names of all individuals who 
were able to accept the invitation are listed in Sub annex lie. 
Typical interview sessions lasted 2-3 hours with the entire Panel present. Three to six 
individuals were interviewed in one session. All interviewees were given in advance a 
short outline of specific points and questions the Panel felt would be important to 
address during the interviews (Sub-annex lid). This gave meetings a structure which was 
easy to manage in terms of time and interaction between Panel members and 
interviewees. We recommend this method to future evaluation panels. We felt that we 
were able to derive valuable information in a relatively short period of time which we 
found invaluable in synthesizing our final report. 
This procedure was not used to guide the presentation from the DGXII managers. The 
presentations were structured by the managers themselves. They were competent and 
summarized the area objectives well and demonstrated the managers' grasp of their areas 
and their enthusiasm. However, much of the information they gave us was summarized 
in documents that were available. These professionals have a vast body of experience 
and information that would emerge more readily if they focused their presentation on 
their impressions, problems they experienced and their own aspirations for future 
programmes. In future, Panels should prepare a list of the questions they would like the 
managers to address, as this panel did with its other interviewees. This could include: 
what problems did you have in managing your areas? Did your coordinators manage the 
science of their projects adequately? Which of the projects in your area was a major 
success and why? Which were failures and why? What will you do differently next 
time? 
For future evaluations we would like to recommend the following: 
1. An increased role of the secretary provided by DGXII to include taking minutes 
during Panel meetings 
2. That the Evaluation Unit provide a mechanism to assist the panel in analyzing 
questionnaires. This assistance could be either monetary to a specific panel member to 
allow recruitment of temporary staff or a contractual arrangement to allow third parties 
to assume the task of entering data and preparing outputs to aid the Panel with the 
analysis of results. 
Sub-annex IIa 
Terms of Reference 
1. The Panel is composed of persons who are appointed by the Director General for 
Science, Research and Development (DG XII), as individuals and not as representatives 
of particular organisations or countries. Their views in no way commit their employing 
organisations. They are required to keep confidential any evidence, written or oral, 
submitted to them that witnesses indicate should be so treated. 
2. The Panel is to evaluate the research and technological development programme in 
the field of biotechnology 1990-1994, the BRIDGE Programme, (Council Decision : 
Official Journal L 360/32 (9.12.89)). 
3. The Panel is to assess: 
- the scientific and technical achievements of the programme taking into account its 
original objectives and milestones and, whenever relevant, of changed circumstances; 
- the quality and practical relevance of the results including commercial developent and 
exploitation and possible spin-offs; 
- the effectiveness of management and the use of resources; 
- the programme's contribution to the development of EU policies and to the social and 
economic development of the EU 
- the benefits resulting from the implementation of the programme at the EU level 
(added value). 
Quantitative indicators will be used whenever appropriate 
The Panel's assessment of achievements and benefits should take into account the 
expenditure applied. 
4. The evaluation should lead to recommendations of the following: 
- the future continuation, alteration or termination of the programme or activity; 
- the management of the programme; 
- the use of research results by organisations carrying out the work; 
- the transfer of technology to other organisations, by movement of personnel, by 
licensing and by other means. 
5. Programme objectives and criteria: 
The specific evaluation objectives and criteria are set out in Annex III of the BRIDGE 
Council Decision (89/621/EEC). 
6. Working procedures: 
Panel members will attend the meetings convened by the Commission in the framework 
of this evaluation. 
Information will be obtained by the Panel from the study of the programme's final 
reports, review papers, policy and other papers, related documents and from mailed 
questionnaires interviews and visits with: 
- project participants; 
- members of the BRIDGE advisory committee (CAN-BRIDGE); 
- members of the Commission advisory committees, (CREST, CODEST, IRDAC); 
- members of the European Parliament; 
- other institutions and organisations; 
- other relevant EU services. 
Subject to prior approval of the Commission, the Panel members may travel within the 
EU to interview persons about the programme and to see work in progress in more 
detail. 
The Panel should take into account the results of previous evaluations. 
The Panel can ask for external assistance in the case of specific scientific knowledge if 
it is required. This is only possible within the available budget. 
7. Evaluation Report. 
7.1 The Panel, assisted by the rapporteur will prepare an interim and a final reportin 
English. 
The Panel is required to produce its interim report by the end of April 1995 for 
discussion with the Commission and to deliver the final report by the end of July 1995 
in a form ready for publication. The Commission will deal with the translations of the 
Executive Summary into other EU languages. The Panel may also prepare a confidential 
annex for the Director of DG XII if it feels that this is desirable and necessary. 
7.2 The interim report should provide the Commission with information concerning: 
- preliminary findings on the programme context, implementations and achievements 
(definitions, call for proposals, selection, contractual conditions, co-ordination, project 
follow-up, distribution of resources); 
- preliminary findings from interviews and how the sample was decided; 
- the data that has been collected and used by the Panel; 
- a synthesis of the activities of the evaluation which have been undertaken; 
- early recommendations if any. 
7.3 The final report will contain the following; 
- an executive summary; 
- a short introduction including a summary of the methodology, 
itinerary and the time schedule followed by the Panel; 
- the main report; 
- any annexes that the Panel consider a useful complement to the report. 
8. The final evaluation report is expected to be published and widely distributed. Among 
others, the Commission will transmit it to the Council of Ministers, the European 
Parliament, the Economic and Social Committee, the European Court of Auditors, 
advisory bodies (CREST, IRDAC, the programme committee), government bodies 
within the Member States, the scientific community and other interested organisations. 
Sub-annex IIb 
Composition of the Evaluation Panel 
Chairman 
Dr. Paul Christou, (GR & USA) 
Head.The Laboratory for Transgenic Technology & Metabolic Pathway Engineering, 
John Innes Centre 
Norwich Research Park 
Colney Lane 
Norwich NR4 7UH, 
United Kingdom 
Rapporteur 
Dr. Norman Carey (UK) 
Consultant, Intellectual Property Management 
Russells Close, High Street 
Chinnor Oxon 0X9 4DJ, 
United Kingdom 
Members 
Prof. Dr. Herwig Brunner (D) 
Fraunhofer­Insitut fur Grenzflachen und Bioverfahrenstechnik (IGB) 
Nobelstrasse 12 
70589 Stuttgart 
Germany 
Dr. Donato Cioli (I) 
Institute of Cell Biology 
43 Viale Marx 00137 Rome 
Italy 
Prof Emilio Muñoz (E) 
Insituto Estudios Sociales Avanzados 
CSIC 
C./Alfonso ΧΠ, 18­5 
28014 Madrid 
Spain 
Dr. Pierre Thuriaux (F) 
Department de Biologie Cellulaire et Moleculaire, 
Centre d'Etudes Nucléaires de Saclay 
F91191 Gif sur Yvette Cedex 
France 
Prof. Bernard Witholt (NL) 
Intitut fur Biotechnology 
ΕΤΗ 
Honggerberg HPT 
8093 Zurich 
Switzerland 
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Sub-annex lic 
Names and affiliations of people consulted or interviewed 
Mr. R.A. Aguilar 
Dr. A.L. Archibald 
Mr. H. Bazin 
Dr. M. Bevan 
Prof. K. Bock 
Mr. M. Cantley 
Prof. B.F.C. Clark 
Prof. S. Daedler 
Prof. C. Daly 
Dr. J. De Brabander 
Mr. J.D. de Nettancourt 
Mr. Ph. de Taxis de Poet 
Dr. P. Donini 
Dr. A. Doyle 
Mr. I. Economidis 
Prof. M. Fonesca 
Prof. J. Frisvad 
EC - DGXII - El - Biotechnology 
Dept. of of Molecular Genetics Edinburgh 
Research Station, AFRC Institute of Animal 
Physiologie, Roslin, United Kingdom 
EC - DGXII - El - Biotechnology 
John Innes Centre, Norwich, United Kingdom 
Head of Department, Carlsberg Laboratory, 
Copenhagen, Denmark 
Head Biotechnology Unit - Directorate for Science, 
Technology and Industry, OECD, France 
Member of BRIDGE-CAN, Denmark 
Max Planck Institute, Cologne, Germany 
National Food Biotech. Center, Cork, Italy 
Member of BRIDGE-CAN, Belgium 
Director of DGXII - H - Human Capital and 
Mobility 
EC - DGXII - El - Biotechnology 
Dept. di Biologica, Cellulare Sez. di Scienze 
Microbiologiche, Università di Roma "La 
Sapienza", Roma, Italy 
European Collection of Cell Cultures, C AMR, 
Salisbury, United Kingdom 
EC - DGXII - El - Biotechnology 
Biotechnology Section, Instituto Superior Tecnico, 
Lisbon, Portugal 
Dept. of Biotechnology, Danmark Teknische 
Hoejskole, Lyngby, Denmark 
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Dr. S.A. Ganguly 
Mr. C. Gitzinger 
Dr. A. Goffeau 
Mr. I. Gustavsson 
Mr. B. Hansen 
Dr. E. Hansen 
Dr. C. Iacobello 
Dr. D. Inze 
Dr. D. Jahn 
Prof. A. Jiminez 
Prof. F.C. Kafatos 
Mr. M. Lex 
Mr. E. Magnien 
Mr. R.C. Martinez 
Dr. S. Martinez-Zapater 
Prof. S. Mayhew 
Dr. M. Mergeay 
Mr. L. Mitek 
Executive Director, Research and Engineering 
Division Unilever, The Netherlands 
EC - DGXIII - D 
Dissemination and exploitation of RTD results, 
technology transfer and innovation 
Formely EC - DGXII - El- Biotechnology 
Dept. of Animal Breeding & Genetics, Swedish 
University of Agricultural Sciences, Uppsala, 
Sweden 
Director - EC - DGXII - E 
Life Sciences and Technologies 
Christian Hansen's Lab., Denmark 
Member of BRIDGE-CAN, Italy 
Genetics Lab., Rijksuniversiteit, Gent, Belgium 
Vice-President Biotechnology, BASF, 
Ludwigshafen, Germany 
Centre for Molecular Biology, University 
Autonoma Cantoblanco, Madrid, Spain 
Director General, European Molecular Biology 
Laboratory 
EC - DGXII - El - Biotechnology 
EC - DGXII -El -Head of the Biotechnology Unit 
EC - DGXII - El - Biotechnology 
Genetics Lab. Biologica Molecular y Virologia 
Vegetal, Madrid, Spain 
Dept. Biochemistry, University College Dublin, 
Ireland 
Laboratory of Genetics & Biotechnology, Vlaamse 
Instelling voor Technologisch, Mol, Belgium 
EC - Secrétariat Général 
Coordination 
Interinstitutional 
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Dr. P. Nolan 
Dr. W. Olijve 
Dr. R. Oliver 
Prof. P. Printz 
Ms. G. Quisthoudt-Rowohl 
Dr. P. Rüdeisheim 
Prof. D. Saccone 
Mme M. Soares 
Mr P. Sourmelis 
Dr. W. Spek 
Prof. C. Tannert 
Dr. Van Dyck 
Mr. F. Van Hoeck 
Mr. R. Van Vliet 
Mr. A. Vassarotti 
Prof. CT. Verrips 
Dr. E. Warmuth 
Dr. N. Whittle 
Biotechnology Unit, Laboratory of the Government 
Chemist, United Kingdom 
Organon International, The Netherlands 
University of East Anglia, School of Biological 
Sciences, Norwich, United Kingdom 
Member of CAN-BRIDGE, France 
Member of the European Parliament 
Plant Genetic System, Gent, Belgium 
CSMME-SNR, Area di Ricerca di Bari, Universita 
di Bari, Bari, Italy 
EC - DGXII - EC Life Sciences and Technologies, 
Responsible for the Administrative Sector 
Formerly EC - DGXII-A6 - Interinstitutional 
Relations 
Member of BRIDGE-CAN, The Netherlands 
Member of the European Parliament 
ATO - DLO, Wageningen, The Netherlands 
Former Director of the EC - DGXII - E 
Life Sciences and Technologies (until 1993) 
EC - DGXII - El - Biotechnology 
EC - DGXII - El - Biotechnology 
Unilever Research Lab., Vlaardingen, The 
Netherlands 
Member of BRIDGE-CAN, Germany 
Cantab Pharmaceuticals Research Ltd., 
Cambridge, United Kingdom 
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Sub-annex ud 
Preparatory questions for interviewees 
1. A brief description of your biotechnology activities 
2. a) If you participated in the BRIDGE Programme: 
a short assessment of your own BRIDGE project stressing the impact on 
your laboratory and on other participants. 
b) If you did not participate in the BRIDGE Programme: 
your main reasons for not participating (and whether you have participated 
in the subsequent EU biotechnology programmes). 
3. Your personal assessment of EU biotechnology programmes: 
impact in your own country 
impact on science at the level of the EU 
the development of EU programmes in relation to National programmes 
shortcomings and desired changes 
4. How do you see the future of European biotechnological research. 
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Annex ΠΙ 
Evaluation of the Project Selection Process 
Introduction 
This chapter is the result of very wide consultation during the evaluation. It includes 
opinions expressed during oral interviews of participants and CAN-BRIDGE, discussion 
with DGXII programme managers, a detailed paper on the process itself prepared by 
one Panel member, (Sub-annex Ilia) and publications from the Commission, (Sub-annex 
Illb) . A response from programme managers clarifying certain points raised in this 
chapter and Sub-annex Ilia is appended as Sub-annex IIIc. All these views and facts 
were extensively discussed by the Panel at a number of plenary session. 
The procedure for the evaluation and selection of projects and its associated management 
appears to be one of the most difficult elements of the Programme on which to obtain 
a firm opinion. Those members of the Panel who have participated in evaluations had 
some unease but were able to understand why this procedure is used. Many of the 
people interviewed expressed dissatisfaction with the process and others presented 
anecdotal evidence of its influence important sections of the scientific community. The 
questionnaires were addressed to successful applicants but even so, they did not show 
substantial approval of the process. The Panel feel it is of fundamental importance that 
the project selection process should receive general support in the scientific community. 
In view of the evidence suggesting serious concerns, the Panel have spent a considerable 
effort to understand the process, its rationale and the apparent causes of the concern. 
We make some practical suggestions and outline some areas of analysis by which DGXII 
and the Commission might achieve greater acceptance of the selection process. 
Description of the Evaluation and Selection Procedure 
It has been constantly emphasised, and the Panel wholeheartedly accepts, that the 
process is designed to select only those projects that promise to be of the highest 
scientific quality. At the same time, the Commission has a number of other objectives 
in funding high quality strategic science and these must be taken into account during the 
selection process. These are, to improve the competitiveness of European industry and 
to foster a pan-European scientific community. 
To ensure the first aim, that research of the highest quality is funded, DGXII maintains 
a panel of experts in the fields of the Programme. These experts are invited in groups 
to review and select projects within their field of expertise. At the time of BRIDGE each 
of these groups numbered a maximum of six experts. This is clearly a review by peers, 
but the fact that the process is so different from those operated by other granting 
authorities, such as the National ones, has led to vigourous and continuing debate as to 
what constitutes a "true" peer review process. There is substance to the question that is 
discussed below. 
The willingness of industry to be involved in the programme is the best way to ensure 
that the Competitiveness aim is being served. This can be achieved at many levels, the 
most visible of which is direct participation in projects. To achieve this, the Commission 
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Officials believe that industry requires almost total confidentiality. Even the fact that a 
company is interested in a project area could be sensitive. 
This perception has led to one of the features of the evaluation, that is, that all the 
project proposals are retained in the Commission offices and never distributed in a way 
that loosens the control over their fate. Confidentiality also extends to the names of the 
Panel of Experts from which the individual reviewing groups are selected. (Of course 
it would be totally unacceptable for the names of experts reviewing particular groups of 
projects to be published). 
The aim of fostering a pan-European scientific community is achieved by the ensuring 
that projects include a true collaborative arrangement between scientists from different 
countries. Once the criteria of scientific quality are fulfilled, the experts are required to 
ensure that each partner is making a true scientific contribution to the collaboration and 
is not included for cosmetic reasons of transnationality. This feature of the Programme 
has not led to problems, indeed it is one of the most positive elements. 
Causes of Concern 
The causes for concern arise mainly from a lack of transparency of the review process 
which in turn results from the perceived need for total confidentiality. Reviewers do not 
see the proposals they are to review until they arrive in Brussels for the meeting. They 
can be unsure of issues or have poor recollection of facts but they have no opportunity 
to check themselves by consulting the literature or colleagues. Any errors they make 
cannot be challenged by proposers since feedback, which is criticised by project 
applicants as minimal, does not occur until after irrevocable decisions are made. The 
Panel believes that this lack of transparency and total reliance on the memory of an 
unknown group of people is one of the main reasons that the process has been 
characterised as not involving peer review. 
The Commission believes that participation by industry requires total confidentiality, but 
those industrialists, ( about 10 to 15) with whom the panel discussed this point, were not 
concerned by it. In any case, the list of contracts and their participants is very soon 
published, and the intention is to publish the results, so confidentiality is not maintained 
for long. Furthermore, the control exercised by the Commission only arises once the 
proposals arrive in Brussels. Before that, while they are being finalised, they must be 
passed between participants laboratories, both industrial and academic. 
The Panel realise that all Community scientific Programmes use the same selection 
process. It may be that some industrial sectors are more concerned with confidentiality 
than others. The biotechnology sections of the Framework Programme are now large 
enough that it would not seem unreasonable to develop mechanisms appropriate to this 
sector. The Panel is aware that the first two VALUE Programmes sent copies of project 
proposals to reviewers some weeks before their arrival at the selection meeting. There 
is no indication that this process caused any difficulty. Nevertheless the VALUE system 
has subsequently been changed simply to bring it into line with other Programmes. 
The development of very large T-projects was also a source of some concern for the 
Panel. Such projects become rather difficult to evaluate for three reasons. First it is 
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difficult to identify suitable evaluating experts from outside the project. The use of 
experts from non-EU countries could overcome this. Second, it is psychologically very 
difficult to reject a proposal from a network that involves a large number of 
laboratories. The third problem is that large networks may tend to develop rules of 
functioning which make it difficult for outsiders to join. These problems do not override 
the value of T-projects, but they should be noted and guarded against. 
Recommendations 
1). The Panel recommends that the list of names of the experts from which the 
reviewing panels are selected should be published. The membership of each review 
panel must remain strictly confidential, but the publication of the total list from which 
each panel is drawn would give individual scientists confidence that their project was 
reviewed by top experts in their field. This would eliminate the criticism that the process 
did not involve peer review since the list would almost certainly overlap with those from 
which peer review would be sought under the various National Programmes. Even 
publication at the end of the programme would help. 
2). The Panel recommends that DGXII seek an independent review of the requirement 
for confidentiality of project proposals by industries involved in biotechnology, given 
that reviewers are at all times under an obligation of confidentiality that includes the way 
they handle documents entrusted to them. This would establish the degree of the need 
for confidentiality. The view should be obtained directly from the companies concerned, 
rather than only from their national or international trade associations. 
3). The Panel recommends that project proposals should be sent to reviewers 2-4 weeks 
before their meeting in Brussels. This would ensure that reviewers could check their 
facts as in all other peer review situations. 
4). The Panel recommends that each reviewer be requested to write a short critique of 
each project reviewed from which a composite feedback paper could be prepared for the 
proposer by the Programme Managers. This feedback would not offer an opportunity 
to reverse the decision but might help in formulating future proposals. Correspondence 
would be entertained for clarification only. 
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Sub-annex lua 
Detailed analysis of the selection process 
Introduction 
The selection process for evaluating grants submitted to the BRIDGE programme was 
identified by many participants and non-participants as one of the main problem areas 
of the programme. Therefore the panel decided to look into it in more detail. We 
collected information from documents supplied by the commission, interviews with 
programme managers, participants, non-participants, CAN-BRIDGE members and we 
also used results from the questionnaires. 
Background 
Four hundred and sixty one project applications were received, corresponding to a total 
request for 430 MECU. It was decided to fund 91 projects including 69 N-projects and 
7 T-projects grouping. 
Evaluation Procedure 
The evaluation of BRIDGE proposals took place over a 6 week period. Four hundred 
and two proposals involving 1884 laboratories were categorized in appropriate topics. 
A panel of 6 experts chosen from a list provided by the Member States (1024) and by 
the Commission Services (237) was coordinated by a staff member of the services of the 
Commission. A total of 184 experts participated in the evaluation process. 
Approximately 25 % of the experts were from industry. These numbers vary slightly 
between different documents (211, of which 12% came from industry). Each evaluation 
session lasted 3 days. On day one, projects were split into 6 equal groups, distributed 
at the start of the meeting to the 6 evaluators, who were asked to exchange their 
proposals every 2.5 hours. One hour was allowed to read each project. Proposals were 
evaluated individually while reading, using evaluation forms provided by the 
Commission. Proposals were rated at this point between 2-4, 2 being high. No top rating 
was to be considered at this point. A selection strategy was then formulated to allow 
only 2 projects to emerge (less than 10% of the total number of proposals). Amongst 
proposals rated 2, some were selected to be eventually attributed the highest rating 1. 
Evaluation forms were returned to the moderator at the end of the 2nd day. On the third 
day, two best projects were proposed (from those rated 1). The entire panel had then 
to establish by consensus 6-12 projects, implying that the third or fourth best choice 
from each individual evaluator be also included if necessary. The projects in the priority 
list were debated for 30 minutes each, and a final mark was attributed to each project. 
Thus, only projects in the priority list were rated twice, once individually and the second 
time collectively. In this case, the second mark was considered to be the final one. 
Representative evaluations are shown in Sub-annex Hid It might be useful to get an 
understanding of how these percentages were arrived at, particularly in grey areas. The 
table below shows first and second ratings for these proposals: 
First rating Second rating 
1. 2.00 1.00 HIGH 
2. 2.00 1.80 HIGH 
3. 2.33 2.17 HIGH 
4. 2.60 2.46 HIGH 
5. 2.60 - LOW 
6. 3.70 - LOW 
At this point, the priority list with projects ranked in the order of their final evaluation 
and the total list with projects ranked through averaged individual evaluations for each 
selection criterion, were transmitted to the CAN-BRIDGE for comments. The list 
included modifications of the proposals in terms of scientific content and scope, 
partners, budget etc., resulting from the expert review, management considerations and 
reviews by other Directorates and Commission Services. We were informed that CAN-
BRIDGE rarely made any further changes to the proposals. 
Identity of an Evaluation session 
Number of evaluators 6 
Nationalities 6 
Academics/Industrialists 5/1 
Duration 3 days 
Number of projects/ 20/110 
participants to be evaluated 
Feedback to the applicant 
DG XII officials were relatively happy about the selection process and the feedback to 
applicants. Our discussion showed that even successful applicants did not agree with this 
perception. Selection criteria, including review procedures for applications, do not seem 
to be very clear and this was an issue that was re-iterated by many participants during 
subsequent interviews as well as many of the respondents to the questionnaires. 
Following evaluation, applicants received a very short report stating that their proposal 
was or was not funded. Applicants were also given a telephone number in Brussels to 
obtain detailed information regarding comments on their proposal. The general 
consensus was that the review process did not generate adequate feedback and 
constructive criticism to help applicants improve their proposal for future applications. 
Criteria followed for the selection of research proposals 
* Test for eligibility by commission services 
* Expected contribution to removal of specific bottlenecks resulting from gaps in basic 
knowledge (N-projects) or from structural or scale constraints (T-projects). 
* Scientific interest of the proposal, originality, feasibility and relevance to the 
workprogramme. 
* Technical competence of the proposers. 
* Multidisciplinarity and integration. 
* Transnationality of participating laboratories. 
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* Industrial interest and involvement. 
* Description of risks possibly associated with the proposed project. 
Comments on Questionnaire sent to Evaluators by Commission 
Following the conclusion of the evaluation procedure, the Commission sent a 
questionnaire to all evaluators to obtain feedback on the evaluation process. The 
following points were raised by the evaluators. The Panel is not aware of actions taken 
by the Commission based on these comments. 
1. Have more time to discuss the methodology of evaluation or alternatively to mail 
the details in advance to the evaluators. (This may have been incorporated into 
later programmes). 
2. One single panel should prepare the priority list for all projects falling within the 
same subtop ic. (This also may have been changed). 
3. Difficulties were found with a particular project of technological priority, because 
of its intrinsic complexity. 
4. Timeliness and inadequacy of re-embursement while in Brussels. 
Questions leading to Recommendations 
1. What is the composition of the Expert list from which Evaluation panels are 
invited? 
2. Projects participants believe a true peer review system involves evaluation panels 
making decisions with input from external referees 
3. What mechanisms exist for ensuring that Commission Staff acting as moderators 
of the panels are impartial? 
4. The result should include a comparison of the priority listing during the second 
stage of evaluation by the experts with the projects that were actually funded 
following the CAN-BRIDGE appraisal. 
5. What are the details of the scoring procedures? 
6. How can feedback to applicants (reviewer's comments, etc) be improved? 
7. Does the system select against high-risk but innovative and potentially rewarding 
projects? 
8. Is mere an opportunity for the project evaluation team to make a post-mortem 
examination of final project reports? 
Highlights on evaluation and selection procedure from questionnaires to 
participants 
EC procedures for making an application for funding under BRIDGE were in general 
found to be straightforward to follow. Documents and information leaflets presented no 
major problems. Respondents from Great Britain had most problems, particularly in 
regard to adequate warning of deadlines and complexity of application forms. 
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When respondents were asked to comment on various aspects of the evaluation and 
selection procedures, they gave the following reactions: 
Speed: In general satisfactory, with most problems coming from the GB, NL, F 
participants. For example whereas in a typical case, Germany would respond as happy: 
18, OK 14, problems: 15, GB would be: happy : 7, OK: 7, problems: 21. 
The following table shows the opinions of respondents from the four major countries 
on the transparency and ease of following of the award procedures: 
Country 
Germany 
Great Britain 
France 
Netherlands 
All other 
countries 
Satisfied 
16 
7 
17 
11 
50 
OK 
14 
11 
13 
16 
30 
Not satisfied 
15 
19 
10 
9 
16 
% not satisfied 
33 
51 
25 
25 
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The next table shows the opinions of respondents from the four major countries on the 
adequacy of feedback of refereed information: 
Country 
Germany 
Great Britain 
France 
Netherlands 
All other 
countries 
Satisfied 
25 
15 
27 
28 
76 
OK 
8 
5 
5 
4 
22 
Not satisfied 
22 
30 
7 
19 
25 
% not satisfied 
40 
60 
14 
46 
24 
There is still a large proportion of those who were successful that still had serious 
problems with feedback (54% satisfied, 32% not satisfied). 
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Sub-annex mb 
Commission publications relating to the 
Project Selection Procedure 
A. Aguilar, January 1993. Highlights of the peer review system followed for the 
evaluation of biotech research proposals.Commission of the European Communities, 
Directorate General XII. R&TD Actions: Life Sciences & Technologies-Biotechnology. 
Anonymous. BRIDGE Breakdown of the selection process. Commission of the European 
Communities 
Anonymous. Notes for the Evaluation Process. Biotechnology (1991-1994) Third Call 
for Proposals. Commission of the European Communities. 
A. Aguilar. April, 1990. Highlights on the procedure followed for the evaluation of 
BRIDGE proposals. Responses to the questionnaire sent to BRIDGE Evaluators. 
E. Magnien and D. de Nettancourt. 1993. What drives European biotechnology 
Research: IJTM. Interscience Enterprises Ltd. Special Publication on the Management 
of Biotechnology. 47-58. 
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Annex IV 
Evaluation of Projects by Programme Area 
Introduction 
The Area Reports are based on a review of the Programme Progress and Final Report 
and other Programme publications, discussions with Participants and examination of the 
responses to the questionnaires. The Panel is aware of the contrast between the necessary 
brevity of the project evaluation reports that comprise this Annex with the large amount 
of literature that relates even to a single project. The review presented is what is 
required for the assessment of the Programme as a whole. Any greater evaluation would 
require a great increase in cost and time commitment. 
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Area Evaluation Ν- Projects 
Area A: Information Infrastructure 
Background 
This area is one of qualitative significance within the BRIDGE Programme, though it 
received only about five per cent of the Programme funds. 
Nine projects were funded in two sub-areas: "Processing and analysis of bio 
(techno)logical data (7 projects); Culture collections (2 projects). 
From the seven projects under the first subarea, five correspond to databases (one on 
nucleotide sequences; two on protein sequences; one on carbohydrates; and the last one, 
on immunoclone and hybridoma). It is worth pointing out that one of them (BIOT-CT-
910271) on "Integrated data and knowledge..." was really a research project and not a 
service. The other two projects fit into the concept of communicating networks (the 
EMB net and the Electronic linking services). 
The two projects in the second subarea reflect the need to foster networking between 
different collections of biological materials. It has been recognised that the important 
national culture collections were seldom known by the industry and the scientific 
community. This lack of awareness hampered the application of this huge amount of 
information to scientific and technological problems. 
Accomplishments 
This area has facilitated the launch and upkeep of a series of databases, and extends the 
understanding and use of bioinformatics through the European Union. 
As can be deduced from the reports (Final Report BRIDGE 1994, volumes I and II) the 
number of users showed a notable increase. Although this is hard to measure in a 
communications system that is freely available and unrecorded, the contract between the 
European Patent Office and the EMBL Data Library, the 50,000 users of the Protein 
Sequence Data bank, the 600 users of the "Immumoclone and hybridoma database" and 
the training impact of the nodes of the EMB net, attest to this increase. 
Evaluation 
There are doubts about the rationale of funding these activities through the mechanism 
of competitive project applications. They are basic infrastructures and services that 
require financial support not only for launching but for their effective upkeep. In spite 
of this, Area A represents a noteworthy effort to build a common infrastructure aimed 
at strengthening the scientific and technological base of all sectors where biotechnology 
will have an influence. 
In view of the importance and specific characteristics of this activity it is proposed that 
a specific sum be allocated to ensure continuity of the operations. These funds should 
be distributed following a periodic review of performance. 
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The sub-area Culture Collections in which modest funding was invested does not show 
many positive results. The scientific community in Europe does not seem to be aware 
of the value of a transnational resource of this kind. Suggestions to correct this might 
include the elaboration of a data base on culture collections, to increase knowledge of 
their existence and to facilitate access by the scientific community. 
Although the Final Report indicates that the ratio of publications per participant 
laboratory is one of the highest of the different BRIDGE Areas. This outcome does not 
seem an important indicator for the evaluation of Area A. The differences between the 
type of project and the qualitative value of publications make comparisons difficult. It 
is important to develop appropriate indicators of success to justify continuation of 
funding of potentially long term infrastructure activities. 
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Area Evaluation Ν- Projects 
Area B: Enabling Technologies 
Background 
Enabling technologies comprised a total of 10 projects in three areas, Protein Design and 
Molecular Modelling (4 projects), Biotransformations (5 projects) and Gene sequencing 
(1 project). Initially there were 52 contracts with a projected expenditure of 7.5MECU. 
This averaged 150KECU per contract with a range of 100-180MECU. The objectives 
of the various contracts concerned the development of methods to overcome some of the 
problems in the development of new molecules and processes. These include methods 
to predict the structure of proteins from their sequence and changes in function from 
changes in structure; methods to control the use of enzymes in the synthesis and 
detection of small molecules; methods to speed up and automate the determination of 
gene sequences. 
Accomplishments 
The achievements within this area were rather mixed. The single project on Genome 
Sequencing did not achieve its main objective of demonstrating the ability of the method, 
a solution phase system, to give a direct read-out of a sequence. The overall aim of the 
project was clearly too ambitious for the resources available. Too many fundamental 
problems needed to be solved at the outset. Nevertheless there is a possibility of some 
spin-off applications. 
The Biotransformation area also had mixed fortunes. The publication record shows that 
some projects had a good output whereas others appear to have had more difficulty and 
publication was rather meagre. Nevertheless, the overall aims of the area were sensible 
and some processes advanced to the point where industrial applications are anticipated. 
Protein design and molecular modelling is an intense field of activity world-wide and the 
applications of the general techniques are frequently of great interest to industry. The 
work carried out in these projects led to some notable advances. There was a substantial 
number of publications, mostly in important journals. These projects show that Europe 
has high quality workers in this field and produces results of international stature. The 
work is truly enabling in that it links to and supports a number of other areas. 
Evaluation 
An overall view suggests that this area merits further selective support. There may be 
some useful applications from the sequencing project but the main aim is likely to be 
overtaken by new mass spectrometry methods. Biotransformation is not yet a commercial 
reality in most fields but it remains a valid approach that warrants selective support. 
Protein design and molecular modelling are clearly important in a number of biology-
based industries and are beginning to have quantifiable commercial impact. The strength 
of the European effort in this field merits further support, since its effect on the 
competitiveness of industry will be immense. 
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Area Evaluations Ν- Projects 
Area C: Cellular Biology 
Physiology and molecular biology of industrial microorganisms 
Background 
A total of 5.1 MEcus was devoted to six Ν projects. Each project typically assembled 
half a dozen European laboratories of good scientific reputation, on subjects that in all 
cases had clear industrial relevance. Great care was obviously taken to ensure a good 
balance of laboratories from all parts of Europe, and four projects had direct industrial 
participation. There is a reasonable blend of industrially important bacteria (Bacillus, 
Corynebacteria and Streptomyces), yeasts (S. cerevisiae and 'non-conventional' yeasts) 
and filamentous fungi (Aspergillus). 
Accomplishments. 
All six projects had a reasonably good publication output. Two of them were particularly 
successful in this respect. It is, however, rather disturbing to see that some of the 
participating laboratories had no publications at all in the final report except those 'in 
preparation'. The 'non conventional' yeast project is the only one that led to a patent 
application which suggests a successful integration of the industrial partner. 
Nevertheless, even the two projects without industrial partners were highly relevant to 
microbial biotechnology exemplifying that there is often no direct correlation between 
industrial participation and industrial relevance in such precompetitive research projects. 
Evaluation 
The overall quality of the research was good. There were some weaknesses but also 
excellent work from some projects or partners, and a clear biotechnological relevance. 
The money spent was notably less than in the other two Cell Biology sectors, for no 
obvious reason. The great potential of recombinant DNA technology for industrial 
microorganisms (including environmental aspects such as bioremediation) is far from 
fully explored. Even without industrial endorsement it would have been a good idea for 
the EU to stimulate research in this area, for example by supporting precompetitive 
projects on microoganisms with promising but still poorly exploited biotechnological 
potential, such as archaeobacteria and cyanobacteria. In this area as in all others, there 
should be more room for young teams and truly innovative projects. 
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Area Evaluation N-Projects 
Area C: Cellular Biology 
Basic Biotechnology of plants and associated microorganisms 
Background 
The biotechnology of plants and related microorganisms was addressed by 13 projects 
worth a total of 9459 KECU, contributed by the Programme. Eighty-five participants, 
13 from industry, representing 15% of the total, took part in the project. Of the 13 
projects, two were concerted actions consuming 30 KECU each. The remaining 11 
projects each consumed between 624 and 1151 KECU. Areas covered by the projects 
included: molecular genetics of development, reproductivebiology, somaclonal variation, 
molecular plant virology, biological control, nitrogen fixation, molecular plant 
pathology, transposon tagging and genes involved in major metabolic pathways. 
Accomplishments 
Major cooperative links were established in almost all the projects with free exchange 
of information, material, technology and personnel. The degree of meeting original 
objectives as set in project descriptions and productivity in terms of publications is 
generally satisfactory. It is difficult to use the number of publications as an objective 
marker of output, without looking in depth at the citation index of specific Journals. 
Evaluation 
In general, projects ran smoothly with no major problems of coordination, interactions 
amongst participants and output. Most of the agreed objectives were met. However, it 
is surprising that so few joint publications resulted from these projects. This is striking, 
as the entire premise of BRIDGE was to foster collaboration across different laboratories 
in different countries. It appears that this was done by meetings and exchange of 
information and materials. Publication records do not reflect the establishment of a truly, 
cooperative environment across the participating laboratories. 
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(4) 
Area Evaluation N-Projects 
Area C: Cellular Biology 
Biotechnology of animal cells 
Background 
This rather heterogeneous subarea had a total investment of 7.01MECU with 59 
participants. It can be further subdivided into 3 groups of projects: 
1. Two projects on expression systems (artificial chromosomes and protein production 
in animal cells), financed with 1.08 and 0.72 MECU, respectively. Although formally 
separate, these two projects had a close scientific relationship with the T-project on 
Animal Cell Biotechnology (meetings were actually held in common). 
2. Three projects on specific animal systems (liver proteins, pig genome, fish genes), 
financed with 0.7, 1.2 and 0.94 MECU, respectively. 
3. Four projects on vaccines against viral diseases of domestic animals (Marek, 
parvovirus, foot-and mouth, herpesvirus-1), financed with 0.54, 0.55, 0.56 and 0.72 
MECU, respectively. 
Accomplishments 
The two projects in group 1 achieved relevant progress in the general biological 
understanding of the basic phenomena involved; in addition, some useful by-products 
(vectors) were obtained that could be of practical applicability. 
The three projects in group 2 all had a high-profile publication output that attests to the 
good quality of results. The success of the PiGMaP project deserves special mention: 
genetic and physical mapping of the pig genome was performed concurrently and in 
integrated fashion in the 18 participating laboratories, resulting, in 3 years, in a 20 
centiMorgan linkage map and in the regional localization of 270 loci on the 19 
chromosomes. The identification on chromosome 4 of genes controlling growth and 
fatness could be of practical importance, while the development of a strategy for the 
study of multigene traits could serve as a model in several human diseases with a 
complex genetic basis. In this case, European science was able to compete successfully 
with a parallel project in the US, due to the network established under BRIDGE. This 
could not have been achieved without the unifying effects of the EU program. 
The four projects on antiviral vaccines were limited in size (3 or 4 participants per 
project) and the publication output was correspondingly reduced. Significant progress 
was achieved in all projects and in two cases an effective vaccine was patented. 
Evaluation 
The vast field of animal cells received under BRIDGE only scattered attention in 
relatively few projects. Success was highest when substantial effort was invested in a 
given problem, while dispersed small projects produced scientifically worthy results, but 
failed to show impressive advances. 
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Area Evaluation Ν- Projects 
Area D: Prenormative Research 
Introduction 
The N-projects of this area were supported by 10 MECU, which is 10 % of the total 
budget of BRIDGE. They were divided into two subareas: 
1. In vitro evaluation of the toxicity and pharmacological activity of molecules 
2. Biosafety 
Neither subarea is normally the subject of academic research efforts. Activities of sub-
area 1 are usually performed in industrial or applied institutional research establishments 
whereas sub-area 2 is a new target provoked by public concern about the deliberate 
release of genetically modified organisms (GMO). 
Twenty-two projects were developed involving 105 participants from 14 countries 
including 3 of the EFTA countries (Austria, Switzerland and Sweden). The duration of 
the projects was 36 months for subarea 1 and 24 months for subarea 2. 
1. In vitro evaluation of the toxicity and pharmacological activity of molecules 
Background 
This research addressed the development of instruments and strategies to replace the use 
of animals in pharmacological experiments, with potentially parallel effects on ethical 
and legal issues. A reduction in research costs may also be possible. This objective is 
within the goals of prenormative research. 
Eight projects were selected, total funding, 4.5 MECU, or 4.5 per cent of the BRIDGE 
programme. The topics of the selected projects were quite diverse, providing a good 
spread of the problems faced by the current research on potential pharmaceuticals. 
Accomplishments 
Important steps were taken in the development of instruments and methodologies. Some 
of them led to validation tests. 
A majority of the projects produced results of industrial interest. 
This subarea had a good publications rate, averaging six publications per participant 
which is among the highest of the Programme. The range, however, was quite large 
amounting to 3 to 12 per participant. Most were in journals of reasonable quality. 
Evaluation 
There is no record of patents arising from projects in this subarea. The significance of 
the validation tests developed appears to be limited since there is no indication that they 
will be accepted by regulatory authorities. 
31 
The participation of industry in the projects was quite limited and in this case may 
reflect on the expected value of the outcome. However, in spite of the value of the 
objectives addressed, the link between pharmaceutical research and biotechnology is 
much broader than that represented by these projects. 
2. Biosafety 
Background 
The subarea Biosafety had the goal of bringing experimental evidence to bear on the 
discussion* Of the environmental effects of the deliberate release of genetically modified 
organisms. This project area was in effect demanded by the public to provide 
information for risk assessment. It is also required by scientists and industrialists who 
need scientifically acceptable model systems and field tests to provide safety data on 
potential products. 
In most cases, at the time of initiation of BRIDGE, the tools were not available to trace 
the GMOs pr their specific engineered genes. It was thought that this subarea would 
provide a sound scientific basis for further discussions. 
Accomplishments 
Fourteen projects were selected with a total funding of 5.6 MECU, corresponding to 
5.6% of the funds of the BRIDGE-programme. The projects were quite diverse, 
addressing releases of genetically modified plants and viruses, the latter for pest control 
and live vaccines. This was the first attempt to fund research on safety and risk 
assessment at the European level. Seven industrial laboratories participated. Some 
advances were achieved in sample preparation and standardisation that could potentially 
form the basis of a spin-off contract research company. 
Evaluation 
In no case did the experiments show a different risk to the environment of the GMOs 
compared to the original organisms. It is not clear that this data has been used in public 
discussion of this issue at any level. 
The duration of the projects on biosafety was limited to 24 months. This is too short to 
assess long term behaviour. This fact was also stressed during interviews with 
participants and coordinators. 
An important advance was achieved in sample preparation and standardisation. This 
could facilitate the transfer of the data collection for risk assessment to spin-off contract 
research companies rather than academic laboratories. 
The publication rate amounts to about 3 per participant with 25% joint publications. 
However, a large proportion were only submitted for publication, and many were 
conference abstracts and EC publications. Two contracts had an unacceptably low 
output. In general publications were in high quality journals of molecular biology, 
microbiology and botany as well as some ecological journals. However, overall this does 
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not necessarily indicate a high level of performance. 
The funds spend on Biosafety were greater than those spent on industrial 
microorganisms. Careful examination of the projects shows that, although this is an 
important area, the Programme supported some projects of questionable merit well 
below the standards of the rest of the Programme. Some did not even fulfill the 
obligatory requirement of transnationality. There is no doubt that pollen transfer between 
related plants occurs. The important questions are whether this produces an 
unacceptable risk or whether the risks can be contained. The projects in this sub-area 
did not address these questions in any scientifically valid way. It would be a mistake to 
perpetuate a culture in which social or political issues dictate that projects should be 
supported regardless of their scientific worth. 
For future programmes the Panel recommends that problems in this area should be 
addressed by high quality research in fundmental ecology. The emphasis should be 
placed on ecological questions related to risk assessment. The Panel is concerned that 
this may not be occuring in current Biotechnology Programmes. 
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Area Evaluation T-Projects 
Yeast Genome Sequencing 
Background 
Successful projects in the preceding Programmes culminated in the publication of the full 
sequence of chromosome III in 1992. The T-project in the BRIDGE Programme was set 
up to sequence two further chromosomes, (II and XI) and to prepare cosmids for the 
sequencing of three more, (VIII, XII and XIV). In addition there were separate projects 
on Informatics and Function Search. The latter is clearly of importance since such a 
large proportion of the putative genes identified have no known function or phenotype 
and no homology with other known genes. The project involved 31 laboratories and was 
expected to spend 5.06mECU over 36 months. Laboratories received 2 ECU per base, 
thus were paid by the amount of work done. 
Accomplishments 
Thejnajor sequencing objectives of this project were achieved in a timely fashion. The 
sequence of chromosome II was published in 1994 and chromosome XI was in press 
in 1995. European laboratories lead the field of yeast genome work at this point. Under 
an international agreement finalised in 1994, the sequencing programme was divided into 
20 genomic regions, 13 whole chromosomes and 7 fragments from the remaining three. 
Of these, 13 were allocated to European laboratories including laboratories not funded 
under BRIDGE and including the 3 chromosomes now completed. The participants 
predicTAthat the sequence of the whole genome will be complete in 1995 and published 
during 1996. They estimate that it will comprise just under 7,000 genes. 
The informatics function continued its successful role in co-ordinating the alignment of 
the sequences produced. Checking systems assessed the average error rate. This was 
lower than previous projects, (99.97% accurate) and much better than other rapid 
sequencing projects. Most sequences are error free. Some have one error and these are 
easily detected if the gene is studied further. More information was obtained on 
chromosome organisation. Gene density and the proportion with no assignable function 
remained as found previously. Some of the novel genes are related to genes in higher 
organisms involved in differentiation or malignancy. 
Evaluation 
This T-project compares favourably with the most successful international scientific 
collaborations. The decision, in about 1987, to set up the original collaboration was 
clearly very far sighted. It faced some opposition and there was considerable pressure 
to add the resources required for this team effort to the international collaboration on the 
Human Genome project. The arguments for a separate yeast effort, and the decision to 
go ahead can now be seen to have many fundamental consequences. Some industries that 
traditionally use yeast may paradoxically be slower to feel the impact but the importance 
for fundamental biological studies, including those that will affect the pharmaceutical 
industry, cannot be overestimated. 
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Area Evaluation T-Projects 
Molecular identification of new plant genes 
Background 
This project centred on three major Research Institutions, involved 22 teams from 13 
different academic and 6 industrial laboratories. It aimed to organise European 
laboratories working on the molecular genetics of Arabidopsis thaliana, at a time when 
this small dicotyledon was increasingly recognised as an important model for plant 
molecular genetics. Haploid plants such as A. Thalania, facilitate the isolation of mutants 
and tha fact that it has a small genome (100 Mio bp) makes it easier to isolate genes. 
The project coincided with National research programmes on the same general theme 
in the UK, DE and FR. It followed a strong development of Arabidopsis research in the 
US and contributed to reducing the gap between US and European efforts. Specific 
themes included physical genome mapping, support to two resource centres, the 
development of gene replacement and gene tagging techniques, combined with research 
on floral induction, seed development and embryogenesis. 
Accomplishments 
Interesting results were obtained in most of the themes, with an excellent publication 
output. Reliable techniques for gene inactivation were not achieved and are in fact still 
an important bottleneck. It would have been useful to see a brief discussion of the 
perfectly good reasons why this objective was not met. Similarly, an important outcome 
of the project was to pave the way for a subsequent sequencing programme launched in 
the Biotechnology Framework Programme. Since the A. thaliana genome is six times 
larger than the yeast genome (but substantially smaller than the genome of all 
economically important plants), a brief discussion of the scientific choices involved in 
the formulation of this Framework Programme would have been most welcome. 
Co­ordination was highly praised by most participants. For administrative reasons, the 
project had to be split into two consecutive grants, which generated excessive paperwork 
and some frustration among participants. This situation, presumably due to constraints 
beyond the control of the DG XII staff, may have damaged the image of European 
research grants in the laboratories concerned. 
A. thaliana is of no direct industrial relevance and the project was clearly of a pre­
competitive nature. It is therefore noteworthy that there were six industrial laboratories 
among the participants. However, the final report makes no mention of the contribution 
of three of them. This project obviously has considerable biotechnological relevance 
beyond that demonstrated by direct industrial participation. Plant biotechnology will gain 
from knowledge based on a tractable model like Λ. thaliana, provided that there is good 
transfer of that knowledge to economically important species. 
Evaluation 
This was a timely, well managed and scientifically productive project, that notably 
contributed to the development of good research on Arabidopsis in Europe. The decision 
to focus on Arabidopsis research in plant biotechnology was undoubtedly an excellent 
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one. Future collaborative European work in this field will require that specific scientific 
choices are made, for example: the relative effort on functional analysis compared to 
sequencing; the organisation of sequencing, (physical gene mapping as opposed to total 
sequencing, cDNA sequencing as opposed to genes); the priority of various physiological 
or pathological functions in the context of a biotechnology programme. 
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Area Evaluation T-projects 
Lipases 
Background 
The project was organised by one main and four sub co-ordinators and included 12 other 
participants. Four of the 17 were from industry. The project addressed six research areas: 
1. 3-D structure and catalytic mechanisms of industrially relevant lipases; 
2. Characterisation of lipases for industrial application; 
3. Structure-function relationship of Pseudomonas and Bacillus lipases; 
4. Digestive tract triacylglycerol lipases and colipases; 
5. Exocellular fungal lipases; 
6. Molecular structure and specificity relationship of microbial triacylglycerol lipases. 
The diversity of the participants in a number of projects, and the fact that three of the 
sub co-or dinators were from industry, resulted in a network that enabled efficient 
industrial use of the scientific results generated by the academic partners. 
The lipase project included many highly productive European laboratories, permitting 
effective use of both the 3-D structural analysis and enzyme catalytic studies for the 
prediction and construction of industrial lipases with desired pH and temperature stability 
for future applications in detergents. 
Accomplishments 
The central question of the mechanism by which lipases are activated by interfaces was 
addressed by investigating the structure, the interfacial binding and the catalytic 
mechanism of digestive tract triacylglycerol lipases and their colipases and of fungal 
lipase (cutinase). 
The research gave rise to several useful and interesting results. These included: 
1. The cloning and overexpression of lipases in the Baculovirus expression system 
among others. 
2. The purification of lipases for crystallisation and kinetic studies. 
3. The crystallisation of several lipases leading to (i) the structure of P. glumae lipase 
which contains a calcium binding site that helps to stabilise the active site and (ii) the 
structure of the Chromobacterium vicosum lipase. 
4. Heavy atom derivatives of B. subtilis lipase crystals were not formed so SDM was 
carried out to identify the possible catalytic triad as Ser77, Hisl56 and Aspl33. 
5. 2-D and 3-D NMR studies of porcine pancreatic prolipase in solution leading to a 
partial solution structure. 
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6. Modelling of P. aeruginosa lipase structures based on sequences and established 3-D 
structures of several lipases. 
7. Insight into the mechanism of "interfacial activation" which involves a shift in the lid 
over the active site of several fungal lipases. 
8. Molecular modelling of the interactions between fatty acid moieties and potential 
binding sites of fungal lipases. 
9. A comparison of the incomplete lid domain of guinea pig pancreatic lipase with the 
complete domain of the coypu enzyme indicating that both enzymes can be active and 
that the intact lid of the coypu enzyme does not necessarily cover the active site. 
10. P. glumae was found to be an excellent potential source of lipases for detergent 
applications. However, it was found to be cleaved by Savinase, (a NOVO subtilisin 
preparation currently used in detergents), at a single site in water and at multiple sites 
at a detergent interface. From the structural studies it may be possible to predict forms 
that will be resistant to proteolytic attack. 
Evaluation 
This was a highly successful project that led to three new 3-D structures via X-ray 
crystallography and models for 7 other lipases based on comparisons with known 3-D 
structures. Suggestions of how lipases may be modified for use in specific applications 
may well be of value to industry. 
The published results were substantial. There were 110 joint and individual publications 
in good to excellent refereed journals and 7 patent applications, illustrating that good 
science and potential industrial applications can be combined fruitfully. 
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Area Evaluation T-Projects 
Lactic Acid Bacteria 
Background 
Lactic acid bacteria (LAB) play a key role in industry. The value of products produced 
with their aid exceeds 100 BECU per annum and they are used in the agricultural 
production of over 200 million tonnes of silage. They are thus the most important group 
of micro-organisms used in the food industry as well as agriculture. 
The objective of this T-project was to advance knowledge of the genetics, molecular 
biology, physiology and biochemistry of LAB and the identification and/or construction 
of improved starter culture strains to meet the requirements of industries that are of 
major economic importance for Europe and thus relieving important bottlenecks in 
production and process applications. The aim was also to enhance culture performance 
and efficiency and generate novel characteristics for new applications. 
The project covered 36 months, 34 participating groups, (7 from industry), from 12 
countries and had a budget of almost 4.9 MECU. 
Accomplishments 
The project encompassed 5 major areas. These were (i) Proteolysis, (ii) Phage and 
Phage Resistance, (iii) Antimicrobials and Molecular Aspects of Food Preservation, (iv) 
Metabolism and Growth in Extreme Conditions, (v) A core activity of Chromosome 
Analysis, Regulation of Gene Expression and Conjugation Systems. 
Major achievements were: 
1. Biochemical and taxonomic classification of over 600 strains involved in various food 
products and processes. 
2. Development of foodgrade systems for stable cloning and controlled expression of 
heterologous genes. 
3. Development of practical strategies for chromosome integration. 
4. Determination of biochemical, functional and genetic properties of proteolytic 
enzymes of L. lactis. 
5. Analysis of the effects of several genetically modified strains on cheese ripening. 
6. Establishment of the full sequence of phages Tuc2009 and blL67. 
7. Development of tools to achieve a higher degree of phage resistance. 
8. Identification and characterisation of novel bacteriocins with structure/function 
relationships, production and mode of action. 
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9. Characterisation of the control of L. lactis lac operon and identification of tagatose-6-
phosphate as the physiological inducer. 
10. Metabolic design of strains with higher yield of flavour precursors, e.g. alpha aceto-
lactate, without lactic acid production. 
Evaluation 
More than 250 joint and individual papers were published, many in highly respected 
journals. More are in preparation or submitted. Seventeen patents were filed, 8 of which 
are now granted. 
This project is one of the most successful undertakings of the EU biotechnology 
programmes. The publication and patent output supports the strategy of fostering basic 
research as a prelude to, and in support of possible industrial applications. Since the 
industrial enterprises depending on LAB are highly decentralised, the outcome of this 
project will have great significance for small as well as large multi-national companies. 
The scientific basis for the application of the tools of modern molecular genetics in food 
production has been substantially enhanced. 
The questionnaires and interviews with participants showed that the project was effective 
in bringing together a critical mass of scientists, integrating smaller countries and 
assisting academic workers to enter a new field in a short space of time. The 
involvement of industry in the planning phase was valuable and it is clear that this 
project is a good example of how to establish a network in the European scientific 
community. Such successes merit further support. 
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Area Evaluation T-Projects 
High Resolution Automated Microbial Identification (HRAMI) 
Background 
The overall aim of this project was to speed up and improve the procedures for 
identifying microorganisms, considered at the time to be a bottleneck in development of 
many biotechnological projects and processes. The specific quite broad objectives were: 
1. To develop molecular methods based on the analysis of macromolecules and antigenic 
determinants for rapid identification of microorganisms; 
2. To develop probes to enable detection and analysis of selected organisms in different 
environments, particularly GMOs (Genetically Modified Organisms); 
3. To assess the utility and compare different methods through the analysis of a common 
set of strains selected from diverse taxa; 
4. To expand the microbial taxonomy base, with emphasis on environmentally relevant 
and uncharacterized microorganisms; 
5. To automate the most promising methods. 
The project started with some delay compared to the rest of BRIDGE (October 1991) 
and received 2.1 MECU, about 2 per cent of the total funds, over a two year period. 
Accomplishments 
The project was highly multidisciplinary since it involved molecular genetics, 
immunology, analytical chemistry, biochemistry, instrumentation and separation 
techniques. This was achieved by forming a group of 10 participants from 6 EU 
countries. The difficulties in managing such a complex, multifaceted project were 
evident. These were overcome by allocating well defined responsibilities to four groups 
with adequate links between them. In addition, a Monitoring Unit consisting of three 
persons representing all parties was given the task of co-ordinating the activities. 
New methods for the application of nucleic acid, lipid and protein analyses to microbial 
identification were developed, and existing methods were improved. Strains and isolates 
of selected problematic and significant taxa (Pseudomonas and mycobacteria) were 
analysed. The data sets were correlated with each other and incorporated into data bases. 
A definitive taxonomy of Pseudomonas was claimed, but this may be exaggerated. 
Evaluation 
The HRAMI Project shows one of the highest ratios of publication output per participant 
laboratory (Final Report BRIDGE). However, the journals where most of the 
publications have appeared stand in the medium to low range of impact. 
This project seems to have suffered from lack of feedback in the project application 
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evaluation procedure. The requirements of the potential users of the project results do 
not appear to have been fully taken into account. There is no information on the link and 
relationship between the output of the project and its participating laboratories with the 
eventual users of products and information. 
The project has some of the characteristics of an information infrastructure project. Its 
aims are horizontal and may be complementary to many other actions of the BRIDGE 
and other BIOTECH Programmes. It could interact with the Information Infrastructure 
Area, the Industrial T-Projects, and the Biosafety Area. 
In retrospect, many of the aims of this project may have been overambitious. For 
example, molecular methods will not distinguish between live and dead organisms which 
may be of crucial concern to some users. 
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Area Evaluation T-Projects 
Animal Cell Biotechnology 
Background 
The 6 sub-projects of this T-project were financed with a total of 2.52MECU for the 24 
participants. Two of the sub-projects had 2 participants, two had 3 and two had 7. 
The overall aim of the T-project was to improve the production of recombinant proteins 
expressed in animal cells. Such a broadly defined area included disparate topics ranging 
from expression vectors (2 projects), post-translational modifications (2 projects), and 
the expression of specific classes of proteins (2 projects). 
Accomplishments 
It is not surprising that results were quite heterogeneous, ranging from rather modest 
achievements to interesting advances. Industrially applicable results were obtained, which 
included various novel vectors and promoters, a study of the media requirements for 
optimal expression and glycosylation, a detailed description of some proteolytic 
processing enzymes and a protein with chaperone activity. Industrial interest was 
facilitated by the creation of the Animal Cell Technology Industrial Platform (ACTIP) . 
A panel of 30 industries were provided with the data arising from the project every six 
months. 
The distinction between N-projects and T-projects adopted under BRIDGE shows its 
limitations in cases like this one: it would not be easy to define this T-project as a clear 
targeted effort towards the elimination of specific bottlenecks resulting from structural 
or scale constraints . The project was rather disperse, with too little investment in each 
specific sub-area, and it could hardly be distinguished from a pool of N-projects. In fact, 
two N-projects were doing very similar work and were participating in joint meetings 
with this project. 
Evaluation 
This project reflects the limited effort that was generally devoted to animal cells under 
BRIDGE. This tendency was modified in subsequent biotechnology programmes, where 
a much larger investment was provided for animal cells and, more recently, for 
biomedical research. 
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Area Evaluation T-Projects 
Plant Cell Growth and Differentiation 
Background 
The major objective of this project was to provide knowledge of the mechanisms by 
which a variety of signals control growth and differentiation. A secondary objective 
was to develop tools at the cellular and molecular levels to render morphogenetic 
events accessible to scientific analysis. It involved an expenditure of 3.9MECU. The 
strategy was to form a team working on the basic mechanisms of growth factor 
perception at the cellular level and the study of key morphogenetic events such as 
somatic embryogenesis, microspore embryogenesis and rhizogenesis. The practical 
objective was to improve the basic knowledge necessary for rendering the regeneration 
of plants a more predictable process. The task was distributed among five groups of 
comparable size in five contracts. These were: regulation of the inductive phase of 
microspore embryogenesis; Plant growth regulators: perception, interaction and 
response; The molecular analysis of higher plant embryogenesis; the Rol genes as 
privileged tools to study plant morphogenesis; molecular analysis of auxin-specific 
signal transduction in plant communication. 
Accomplishments 
Some of the major achievements of the programme were: the delineation of the role 
of secreted proteins and glycoproteins in the regulation of somatic embryogenesis; the 
discovery of genes and gene products involved in several aspects of cell differentiation; 
the production of tools for use by the wider scientific community. A variety of nucleic 
acid probes, mutated genes, gene constructs, transgenic plants, antibodies, 
oligosaccharides, new ligands, cell lines etc., were prepared and distributed widely. 
This led to the initiation of 110 joint experiments. Up to December 1993, more than 
200 papers have been published describing the results of the project. This number will 
probably increase dramatically when the project is concluded. A newsletter, T-News 
was created at the start of the project and this served as the internal link between the 
participating research groups. Three to six sectoral meetings for each sub-project area 
and three general meetings were organized. More than 30% of the papers published 
involved researchers from different laboratories and about 20% corresponded to 
publications with transnational authorship. 
Evaluation 
The project addressed fundamental issues in plant biotechnology. It provided new 
information, tools and technology for participants and the wider scientific community. 
A number of the outputs of the project were taken up by industry. Industrial 
laboratories comprised about 13 % of the project team. Results from some project areas 
provided a biochemical understanding of fundamental plant processes and were 
impressive. The training component of the programme was strong and this was 
reinforced by encouraging postdoctoral fellows to interact with other members of the 
project and to attend sectoral and general meetings. The creation of a Plant Industrial 
Platform (PIP) was also a means to disseminate results and technology. 
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Annex V 
Impact of the BRIDGE Programme on the 
EU Biotechnology Industry 
Measures to establish the impact of the BRIDGE Program on industry include: the 
involvement of project participants with industry during their BRIDGE project; the 
output of individual projects with respect to publications, patent applications and use of 
the results by industry, and development of post BRIDGE projects together with 
industry. 
The involvement of University and Institute groups with industry was not equally 
distributed in Europe. A number of indicators shows that such interactions were best 
developed in the Netherlands and the United Kingdom, were rather less developed in 
France and Germany, and were sporadic in other European countries. This pattern is still 
seen today, although project participants were often optimistic about post BRIDGE 
activities with industry. Many participants developed links with industry as a result of 
being involved in a BRIDGE project, and generally felt that having carried out a 
BRIDGE project increased the opportunities for future industrial collaboration, while not 
impairing access to National funding. 
Industry participated directly in about 11 % of the BRIDGE projects. Of the respondents 
to the questionnaires, 6 of the 52 co-ordinators (12%) and 20 of the 262 partners (7.6%) 
were from industrial laboratories. These samples are too small to allow clear statements 
about the perceptions and experience of industrial versus non-industrial participants, but 
no obvious differences seem to emerge. 
However, since only 11% of the projects involved direct industrial participation it 
suggests that a large number of potentially eligible industries did not participate. The 
Panel therefore decided to conduct a limited and informal poll of leading protagonists 
in biotechnology industries, located throughout Europe, most of which had not 
participated in the BRIDGE Programme. 
To this end the Panel contacted directors or senior managers of general and 
biotechnology R&D companies, and asked for their views on European and National 
biotechnology programmes via a short questionnaire. Half of the responding 
biotechnology leaders were from established large European companies or sophisticated 
smaller research intensive biotechnology companies with at least 100 employees, and half 
of the respondents lead smaller or less sophisticated biotechnology industries. The Panel 
was particularly interested in determining whether these industries were aware of the 
BRIDGE programme and other relevant European programmes; why eligible industries 
did not participate in the BRIDGE Programme; and how they valued European and 
National biotechnology programmes. The results of this poll are given in Annex Vic and 
discussed below. 
About half of the 37 industrial leaders polled had been aware of the BRIDGE 
Programme, and most were aware of subsequent European Biotechnology Programmes. 
The general feeling among these industrial leaders is that European Programmes are 
important to their industries in an indirect manner, by creating a European scientific 
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community. Industry did not regard these programmes as the right place to access 
specific results such as patentable knowledge, nor have they been designed to support 
new industrial approaches and strategies. National biotechnology programmes were seen 
as more appropriate for the latter purposes. 
It is interesting that, despite the lukewarm perception of National and European 
Biotechnology Programmes by industrial leaders, virtually all felt that both National and 
European funding for such programmes should be expanded by amounts ranging from 
10 to 100%. Leaders from smaller companies tended to favour higher increases 
suggesting 50-60% increases for national programmes and 35% for European 
programmes. Those from larger companies favoured increases of 20% and 25% for the 
national and European programmes respectively. The industrial biotechnology leaders 
felt that about 35% (small companies) to 45% (large companies) of the available 
government funds for biotechnology in Europe should be distributed via European 
programmes. The réponse from the leaders of small compames resembled that of the 
participants in the BRIDGE Programme who, although giving a wide range, averaged 
35 % in response to a question about how much of total biotechnology funding should 
occur via European programmes. 
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Annex VI 
Main findings of the Questionnaire Surveys 
Introduction 
All participants in the BRIDGE programme received questionnaires either as co­
ordinators or partners of projects. The questionnaires were sent out by the evaluation 
unit of DGXII and responses were returned to the Institute of Biotechnology, ΕΤΗ 
Zurich Switzerland, where they were analysed. 
Of the total of 91 funded proposals and 579 participants in the Programme, 52 Co­
ordinators (57%) and 262 partners (53.7%) responded, an overall response of 54%. 
Both questionnaires are appended as Sub­annex Via and Sub­annex VIb. These annexes 
include a summation of the quantitative data obtained from the responses. The data were 
analysed by splitting responses according to the country of origin of the respondent, and 
in some cases, according to the project area. 
Interpretations based on the overall data and on country data are given below. 
Project Area 
Table 1 shows the distribution of the N­project and T­project areas and the responses of 
co­ordinators and partners in each area. The response was well distributed for both co­
ordinators and partners, with the exception of the co­ordinator response for a few T­
projects. 
Table 1 
Project Area 
Information 
Infrastructure 
Enabling 
Technologies 
Cellular Biology 
Prenormative 
Research 
Yeast Genome 
Sequencing 
New Plant Genes 
Lipases 
Lactic Acid Bacteria 
HRAMI 
Animal Cell 
Biotechnology 
Plant Cell Growth 
Factors 
Totals 
Co-ordinators 
responding 
2 
9 
12 
9 
0 
1 
3 
1 
0 
4 
5 
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Partners responding 
18 
23 
57 
35 
19 
20 
16 
25 
6 
14 
14 
252 
% response 
Co-ordinators 
22 
90 
43 
41 
0 
12 
60 
100 
0 
67 
83 
45 
% response 
Partners 
55 
55 
37 
42 
66 
100 
84 
76 
67 
78 
58 
54 
47 
BRIDGE Programme Initiation 
It is interesting to trace the sources of the different projects and the roles that were 
played by co-ordinators and partners. 
Of the 52 responding co-ordinators, 12 (23 %) provided input into the formulation of the 
scientific objectives of the overall BRIDGE Programme and 10 (19%) did so directly via 
Commission (DGXII) staff, with co-ordinators from GB, IR, D, F and NL being most 
active in this respect. Of the 262 partners, 69 (26%) provided input, however, only 29 
(11 %) did so via Commission staff. The greatest influence was exerted by partners from 
NL, D and I. 
Setting up Proposals 
The majority of partners (56%), became aware of the BRIDGE call for proposals via 
personal contacts with other scientists, while about 18% and 19% respectively became 
aware via contacts with DGXII staff or through National authorities or representatives. 
Very few partners became aware of the BRIDGE proposal call via the Official Journal 
of the EU or through the scientific press. This general pattern was seen for partners 
from all of the EU member states. 
For co-ordinators, awareness of the BRIDGE proposal call came about equally through 
contact with DGXII staff, National authorities and personal contacts with other scientists. 
Of the 52 co-ordinators, 34 (65%) were primary instigators of the proposals and they 
were highly influential in selecting partners. Some co-ordinators, (20%), contacted 
potential partners who declined to join the team. About 70% of the co-ordinators made 
new contacts in setting up the project. The selection of partners was determined by 
scientific reputation, technical expertise and previous collaboration. Geographical balance 
was a minor factor in the selection of partners, and the EU requirement for transnational 
projects was seen as a hindrance by only 8 % of the co-ordinators. Half the co-ordinators 
saw this requirement as neutral and the rest saw it as helpful. About 40% were assisted 
by their home institution in setting up the project. Half sought help from EU officials 
in setting up their proposals, mainly for clarification of procedures, terminology and 
documents. 
In 60% of projects, co-ordinators were asked by the BRIDGE management to modify 
their projects, most often by reducing their funding request and in several cases by 
combining with other proposals. Half the co-ordinators were content with the resulting 
changes. 
Of the 262 partners, only 15 (6 %) were primary instigators of the proposals. Nearly half 
belonged to a group of existing collaborators, while the other half was invited to join 
such groups. Most, (80%), made new contacts in setting up the project. About 10% saw 
the EU requirement for a spread of participants as a hindrance, 54% saw this as neutral 
and the rest considered it as helpful. Only 30% of the partners were aided by their home 
institutions in setting up the project. Only 28% sought help from EU officials in 
preparing their proposals, mainly for clarification of procedures and to a lesser extent 
for help with terminology, documents and guidance on research categories. 
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Funding and Scientific Networks are major reasons for initiating a BRIDGE project 
Major motives for applying for BRIDGE funding for both co-ordinators and partners 
were access to funding, access to scientific expertise and establishing a network for 
future collaboration. Prestige and possible business reasons (partnership, access to 
products, access to sales, market intelligence) were negligible factors in setting up 
projects, and interestingly, technical expertise was also unimportant in this respect. 
BRIDGE funding clearly supplemented rather than replaced National funding and for 25-
20% of partners and co-ordinators it has been a stimulus to obtaining further National 
funding. 
BRIDGE projects support ongoing work 
About 90% of the partners and co-ordinators carried out related work prior to the 
initiation of the BRIDGE project, funded from National sources, University or other 
intramural funding, other European funding or industry funding, in that order. Both co-
ordinators, (70%), and partners, (64%), had had collaborations with one or more of the 
other partners before the BRIDGE project commenced. These collaborations generally 
involved joint experiments, exchange of materials, data and personnel as well as training 
of PhDs and post-docs. 
The BRIDGE project was well embedded in the ongoing research of the project 
participants. BRIDGE-funded work was connected with other projects in the laboratories 
of most co-ordinators, (80%), and partners (72%). 
Almost all of the partners and co-ordinators (about 90%), continued work on the project 
post-BRIDGE via National programmes, University or intramural support, a European 
programme and in a limited number of cases, via industry, i.e. via those channels that 
funded the project pre-BRIDGE. 
Almost all the partners and co-ordinators (90-95 %)also plan to continue collaborations 
with one or more of the partners. Despite the clear continuity of these projects both pre 
and post-BRIDGE, most participants (about 65-75 %) felt that the present collaboration 
would not have occurred if the BRIDGE project had not taken place. 
It is interesting that, although industrial partners played a minor role in the projects, 
about half of the participants reported that the continuation projects would involve 
industrial collaborators. Apparently, industrial interactions have grown post-BRIDGE. 
Whether this was a result of the BRIDGE Programme or independent of it has not been 
established. 
The application and award procedures were perceived with mixed feelings 
A questionnaire sent to all participants showed that 57% (150/262) felt the application 
procedures were difficult to follow (rating them 3 or above on a 1 to 5 scale) with 10% 
giving the worst rating. A related question on the clarity of these procedures gave almost 
identical figures. Finally, 39% felt that warning on application deadlines was inadequate. 
The same questions were addressed to project coordinators, who had a closer contact 
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with DGXII, and the figures were not very different (50%, 38% and 42% respectively). 
In summary, applying to BRIDGE appeared to be an unduly complicated affair. The 
complexity of die application forms must have been recognised, since these forms are 
more streamlined in die present Biotech programmes. Whether this really simplified the 
situation for the applicants remains to be seen. 
Both co-ordinators and partners were unhappy about the project evaluation and selection 
procedures. The procedure was considered to be average for speed, somewhat obscure 
and rather difficult to follow, and the feedback of refereed information was considered 
inadequate. Since these are the views of European researchers who were successful in 
gaining support from BRIDGE, it is likely that the views of the many who were not 
supported would have been even more critical. This is one area in which improvement 
is essential if European science programmes are to gain widespread support, respect and 
appreciation from the European scientific community. 
Operation and management of the project 
The co-ordinators were reasonably satisfied with the help they received from the EC 
management in administering their projects and most (70%) felt that the EC managed 
the distribution of funds efficiently. 
The co-ordinators were rather satisfied with the co-ordination of their projects and nearly 
90% received help from other partners in preparing proposals. Apparently co-ordination 
is a satisfying task since 88% would co-ordinate another EC funded project. It is 
interesting that the partners were even more satisfied than the co-ordinators with respect 
to project co-ordination. 
Many co-ordinators (61 %) ran a formal project monitoring system, mostly via written 
annual or half-yearly reports and meetings. 
On the whole, both co-ordinators and partners found the co-operation to be reasonably 
easy. In the more difficult collaborations, problems were caused by a single partner in 
half the cases and by most of the partners in other cases. Difficulties with non-delivery 
of promised results, technical and administrative problems predominated and, in some 
cases, personality problems occurred. Language was rarely a source of problems. 
In most cases the transnational collaboration required by the EC significantly facilitated 
the achievement of the scientific and technical goals, (70% according to both co-
ordinators and partners). The achievement of scientific and technical goals was hindered 
in fewer than 4% of the project according to both co-ordinators and partners. 
In most cases, new personnel were recruited for the BRIDGE project, generally from 
the same country and less frequently from other EC countries. Notable exceptions are 
Italy and Portugal, where National regulations apparently prevented recruitment of 
personnel. National authorities should be urged to remove such serious obstacles to a 
fruitful investments of research funds. 
50 
Output of the projects 
A large majority of the co-ordinators (85%) and partners (75%) felt that unexpected 
results were obtained in their projects. Most of these were scientific results although 
there were also unexpected results relating to the quality of inter-laboratory contacts and 
in generating new academic and to some extent, industrial contacts. Unexpected 
intellectual property and unexpected product opportunities were clearly less frequent. 
Other interesting effects were increased industrial interactions of academics and 
increased access to National funding. It is rather astonishing that no co-ordinators and 
only 2-3 % of partners consider National funding harder to obtain as a result of EU 
funding via BRIDGE, while none feel that EC funding has made it harder to develop or 
finance industrial collaborations. In fact, 30-40% of the partners and 40-50% of the co-
ordinators reported that following EU support for BRIDGE projects, it was easier to 
develop National and industrial projects and funding sources. 
Future Biotechnology funding in Europe 
Virtually all project participants feel that more funds should be spent on biotechnology 
research both at the European level and Nationally. In a separate survey, the Evaluation 
Panel found that this feeling is shared by industry, even when those industries do not 
benefit directly from European or National programmes. 
Given the reality of limited European funding possibilities, about one third of 
participants opted for more projects with smaller contributions per project, while roughly 
one third preferred larger projects, of which fewer would then be carried out. The 
remainder were not interested in limiting resources and wanted to see more projects with 
equal or more resources than available via BRIDGE. 
Given that ultimately total funds for biotechnology or other research will be limited, the 
participants felt that it would be appropriate to disburse about 25-30 % of these funds via 
European programmes while 70-75% should be disbursed via National programmes. 
Here also industries with an interest in biotechnology tended to favour more EU and less 
National control over total biotechnology research and development spending. 
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Sub-Annex Vla1 
BRIDGE EVALUATION QUESTIONNAIRE 
FOR CO-ORDINATORS 
General instructions. Where questions require a "Yes" or "No" answer, please circle 
the chosen word. In all other cases where there are multiple choices, please tick above 
the line next to your answer. Some questions can have more than one answer. These 
are indicated. 
I . Personal and project details. 
1. Name and address: Responses were obtained from 52 individuals 
2. Contract number 
3. Project title 
4. Project area, tick one: 
N-Projects: 
2 A. Information infrastructure 
9 B. Enabling technologies 
12 C. Cellular Biology 
9 D. Pre-normative Research 
T- Projects: 
0 Tl Yeast Genome Sequencing 
1 T2 Molecular Identification of New Plant Genes 
3 T3 Lipases 
1 T4 Biotechnology of Lactic Acid Bacteria 
0 T5 High Resolution Automated Microbial Identification 
4 T6 Animal Cell Biotechnology 
5 T7 Factors Regulating Plant Cell Growth and Differentiation 
In the questionnaire Annexes, only numerical summation of the responses is given. 
Narrative and other comments are of necessity omitted. 
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Π. Initiation of the BRIDGE Programme 
1A. Did you have any input into the formulation of the scientific objectives of the 
overall BRIDGE Programme? 
Yes 12 No 38 
IB. If yes, was this: 
2 a) Indirect, through national representatives 
10 b) Direct, through Commission staff 
2 c) Other, (please specify) 
ΙΠ. Setting up your contract proposal. 
1. How did you become aware of the BRIDGE call for proposals? 
2 a) through the Official Journal of the European Union. 
19 b) through contact with DG XII staff 
18 c) through National Authorities or representatives 
8 d) through the scientific press 
20 e) through personal contact with other scientists 
1 f) other, please specify. 
2. Were you: 
34 a) the primary instigator of the proposal, 
13 b) one of a group of existing collaborators 
4 c) invited to join a group assembled specifically to prepare a 
BRIDGE proposal 
0 d) Invited to join the group after the proposal had been 
substantially formulated. 
3. How were partners in the group selected? (multiple answers permitted) 
44 a) by you as co-ordinator 
30 b) by other members of the group 
3 c) by suggestions from the EC management 
8 d) by partners offering their services. 
Please indicate the most important factor if more than one is chosen 
4A. Did you make any new contacts during the process of setting up the project. 
Yes 35 No 16 
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4B. If yes, were they: 
36 a) Academic 
21 b) Industrial, 
and c) please specify from which countries 
5A. In preparing the Bridge proposal, did you contact potential partners who declined 
to join the team? 
Yes 10 No 41 
5B. If yes, how many were: 
4 a) Academics 
66 b) Industrialists 
5C. Please summarise the main reasons for refusing: 
a) Academics 
b) Industrialists 
6. In developing the contract proposal, did you find that the Programme requirements 
for a spread of participants from a number of Community countries was: 
19 a) a help 
4 b) a hindrance 
26 c) neutral 
7. Did your home Institution, (Contracts Officer, Industrial Liaison Group or 
others), help in setting up the project. 
Yes 22 No 30 
8. What factors affected the mix of partners in your group? 
14 a) geographical balance 
38 b) scientific reputation 
38 c) technical expertise 
29 d) previous collaboration 
3 e) other, please specify. 
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1 
28 
14 
4 
1 
7 
12 
0 
2 
5 
10 
6 
1 
6 
10 
0 
3 
4 
11 
7 
3 
5 
6 
0 
a) 
b) 
c) 
d) 
e) 
f) 
g) 
9. Which countries are represented in your project team? 
14 a) Belgium 11 b) Denmark 26 c) France 
34 d) Germany 5 e) Greece 11 f) Ireland 
22 g) Italy 0 h) Luxembourg 27 i) Netherlands 
5 j) Portugal 18 k) Spain 32 1) UK 
9 m) EFTA countries 
10. What were your main motives in applying for BRIDGE funding? Please select 
three in order of importance, by marking 1, 2 and 3. 
Access to funding 
Access to scientific expertise 
Access to technical expertise 
Prestige 
Limited National funding 
To establish a network for future collaboration 
For business reasons, (partnerships, access to products, 
access to sales, market intelligence, etc.) 
1 0 1 h) Other, please specify 
11. Has your BRIDGE funding: 
4 a) Replaced earlier National funding 
18 b) Been a stimulus to obtaining further National funding 
26 c) Supplemented National funding 
12A. Prior to the award of the BRIDGE funding did you carry out work related to 
this project? 
Yes 47 No 3 
12B. If Yes, which of the following was the source of this funding: 
University or other intramural source 
National programme 
Industry 
Non-Government/Charity/Private funding 
a European programme 
EUREKA 
other international programmes 
other, please specify 
15 
29 
14 
5 
15 
0 
2 
1 
a) 
b) 
c) 
Φ 
e) 
f) 
g) 
h) 
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13A. Was the project, during its lifetime, co-ordinated with or related to other 
projects within your lab with funding from the above sources? 
Yes 41 No 10 
13B. 
14. 
If yes, indicate the relevant funding source: 
During the period of this project, how many people in your laboratory, not 
funded by the BRIDGE project, were working on related areas? 
15. In which other EC Programmes have you participated? 
IV. Project Application and Award Procedures. 
1. How did you find the EC procedures for making an application for funding under 
BRIDGE? 
Easy to follow. 
1 
4 
2 3 
21 12 
4 
10 
5 
4 .Difficult to follow 
Documents and 
information leaflets 
clear 28 10 
Documents and 
information leaflets 
clear unclear 
Warning of deadlines 
adequate 23 13 
Warning of deadlines 
inadequate 
2. How did you find the project evaluation and selection procedures? 
Quick. 
1 2 3 4 5 
5 11 20 12 1 .Slow 
Transparent/easy to 
follow 6 12 17 11 
Obscure/difficult to 
follow 
Adequate feedback 4 5 11 15 16 Inadequate feedbac of 
of refereed information refereed information. 
3. What is the single most important improvement which you would propose to the 
procedures of calling for, selecting and awarding project proposals? 
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4A. Did you seek help from EC officials in preparing your proposal? 
Yes 26 No 25 
4B. If yes, Did this include: 
16 a) Clarification of procedures 
11 b) Clarification of documents 
12 c) Clarification of terminology 
5 d) Guidance on categories of research 
3 e) Other, please specify 
5A. Was your project modified by the BRIDGE management before being awarded? 
Yes 30 No 21 
5B. If Yes, were you requested to: 
26 a) reduce funding and by what percentage 
2 b) include additional objectives 
2 c) reduce the number of objectives 
4 d) include additional partners 
7 e) combine with other proposals 
2 f) other, please specify: 
5C. Are you content with these changes, if any? 
Yes 12 No 13 
Comments: 
5D. If you were requested to combine with other proposals, as suggested in 5B (e) 
above, did this result in duplication of expertise in the project group? 
Yes 1 No 9 
Comments: 
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V. Operation and Management of the Project. 
1. Has the distribution of funds to you as co-ordinator and to the partners been 
efficiently managed by the EC? 
Yes 35 No 15 
2. Are you satisfied with the help you have received from the EC management in 
administering the project? 
1 2 3 4 5 
Satisfied 16 17 12 5 0 Not satisfied 
3. What is the single most important improvement the EC management could make 
which would have assisted you? 
4. Are you satisfied with the coordination of the project? 
1 2 3 . 4 5 
Satisfied 17 22 4 6 0 Not satisfied 
5. Was the percentage of your time required to run the project greater than 
expected, less than expected, or about the same as expected? Please indicate: 
a) the expected percentage % 
b) the required percentage % 
6. Were the reports required by the EC: 
15 a) too early in the project 
7 b) too frequent 
1 c) too infrequent 
0 d) requiring too much scientific detail 
6 e) too focussed on adminisrative detail 
7. Did you receive help from other participants in preparing proposals? 
Yes 44 No 8 
8A. Would you co-ordinate another EC funded project? 
Yes 46 No 6 
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8B. Can you give reasons? 
9A. Did you operate a formal project monitoring system? 
Yes 32 No 19 
9B. If yes, did this include: 
a) written reports: 
b) oral reports: 
2 
9 
15 
17 
32 
(i) 
(ii) 
(iii) 
(i) 
(ii) 
quartly 
half-yearly 
annually 
by telephone 
at meetings, (indicate 
frequency) 
10. Was the co-operation between the partners, on average, easy or difficult? 
Easy 
1 2 
15 17 
3 
9 
4 
6 
5 
2 Difficult 
11. For scores of 3 and above, was the difficulty focused on: 
9 a) one partner 
9 b) about half the partners 
2 c) essentially all the partners 
12. Were the problems largely: 
7 a) technical 
14 b) non-delivery of promised results 
8 c) administrative 
2 d) language 
9 e) personality 
4 f) other, please specify: 
Any other comments: 
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13. Did the transnational collaboration required by the EC facilitate or hinder the 
achievement of the scientific and technical goals? 
36 a) Facilitate 
2 b) Hinder 
11 c) No impact 
14A. Have you had collaborations with any of the partners before the project 
commenced? 
Yes 36 No 14 
14B. If yes, with how many? 
14C. Did they involve: 
9 a) Literature work, (reviews etc) 
28 b) Joint experiments 
29 c) exchange of materials 
27 d) exchange of data 
19 e) exchange of personnel 
6 f) training undergraduates 
9 g) training of PhDs 
9 h) training of post-docs 
15A. Are you or will you be continuing collaboration with any of the partners? 
Yes 49 No 2 
15B. If yes, with how many? 
15C. Would this collaboration have occurred if the project had not taken place? 
Yes 9 No 33 
VI. Personnel 
1A. Have personnel been recruited into your laboratory specifically for the project? 
Yes 43 No 7 
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IB. If yes, indicate the number of staff hired in the following categories: 
9 a) from other projects in the lab 
35 b) from own country 
19 c) from other EC countries 
(name countries) 
8 d) from non-EC countries 
(name countries) 
1C. Indicate the number of staff recruited to the project in your laboratory in the 
following categories: 
Scientific 
Technical 
Administrative 
2. How many staff were retained in permanent posts? 
Vu. Output of the Project. 
1. Please list the three most important objectives identified at the start of the 
project. In each case, what percentage of the original milestones of this project 
were met? 
a) Objective 1 Percentage met 
b) Objective 2 Percentage met 
a) Objective 3 Percentage met 
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2. What were the reasons for non-achievement of objectives? 
6 a) Unrealistic formulation of objectives 
16 b) Scientific* 
7 c) Technical limitations (please specify) 
8 d) Inadequacy of funding 
1 e) Limited availability of equipment 
0 f) Poor management by the EC 
7 g) Poor cooperation between partners 
13 h) Other (please specify) 
* e.g. new information rendering the original objective obsolete impossible or 
unnecessary. 
3A. Did the project have results which were unexpected or could not have been 
predicted before the work started? 
Yes 44 No 8 
3B. If yes were these results: 
44 a) scientific 
16 b) in the quality of inter-laboratory contacts 
16 c) in generating new academic contacts 
16 d) in generating new industrial contacts 
12 e) in generating intellectual property 
9 f) in generating new product opportunitie$ 
1 g) other, (please specify) 
VIH. Meetings and Exchanges 
1. Have you had contact with the EC Committee of Advisory Nature for BRIDGE, 
(CAN-BRIDGE), from your country during the project? 
5 a) More than 5 times 
12 b) Less than 5 times 
34 c) Never 
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47 
40 
31 
49 
43 
45 
4 
a) 
b) 
c) 
d) 
e) 
f) 
g) 
2. Indicate the level of interaction by the project partners: 
Attendance at combined project meetings. Number of meetings 
Visits between Principal Investigators of partner labs 
Exchanges of research staff. Number of researcher weeks 
Sharing of data 
Exchanges of protocols, software etc. 
Exchanges of materials, cell lines etc. 
other, specify 
3. Have you made any new contacts other than participants as a result of working 
on the project? 
Yes 46 No 6 
4. Are these contacts, or work with other participants, leading to further project 
proposals or collaborations? 
Yes 38 No 10 
IX. Dissemination. 
1. Indicate the importance of the following dissemination routes on assessing the 
success of the project and try to quantify the expected output. 
a) 
b) 
c) 
d) 
e) 
f) 
g) 
h) 
i) 
J) 
k) 
1) 
Publication in 
refereed journals 
PhD theses 
Other technical 
publications 
Conference 
presentation/abstracts 
Patent application 
Software 
New methods 
Standards 
Prototypes or 
pilotstudies 
New products 
New services 
Other, please 
specify: 
Primary 
Output Route 
45 
13 
6 
28 
12 
3 
11 
4 
3 
6 
5 
2 
Secondary 
Output Route 
6 
22 
14 
11 
9 
4 
8 
3 
3 
1 
3 
2 
Expected Output 
Number 
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2. Which of the following will be the main users of the results of your project? 
35 a) Academic scientists 
26 b) Industry 
2 c) Other, (please specify) 
3. If the main user is industry, in which of the following categories is it having or 
is expected to have an impact? 
Current Expected 
a) acadeniic-industry contracts 15 8 
b) patents adopted by industry 4 6 
c) product development by industry 10 11 
d) marketed product 3 2 
Xv Post-Programme Considerations 
1A. Is research continuing in your laboratory on the topic of the BRIDGE 
Programm /^? 
Yes 47 No 4 
IB. 'If yes, please give the source of funding: 
21 a) University or other intramural source 
27 b) National programme 
12 c) Industry 
5 d) Non-Government/Charity/Private funding 
21 e) a European programme 
0 f) EUREKA 
1 g) an international programme 
2 h) Other, please specify 
2. Does the continuation project involve any of the same personnel? 
Yes 40 No 8 
3. Does the continuation project include any of the same collaborators? 
Yes 41 No 5 
4. Does the continuation project include any industrial collaborators? 
Yes 25 No 19 
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5. Has EC funding affected the development of your group and your activities by 
making National funding? 
21 a) easier to obtain 
0 b) harder to obtain 
29 c) unchanged in this respect 
6. Has EC funding affected the development of your group and your activities by 
making industrial projects? 
26 a) easier to develop or finance 
0 b) harder to develop or finance 
23 c) unchanged in this respect 
7. About 20% of proposals submitted to BRIDGE were funded, the average EC 
contribution being 0.77 million ECU per total project. In your opinion would it 
have been preferable to have: 
14 a) more projects, each receiving < 0.77 million ECU 
12 b) fewer projects, each receiving > 0.77 million ECU 
16 c) other, (please specify) 
8A. Several EC countries feel that they should reduce funding National programmes 
as funding via EC programmes increases. Assuming that EC and National 
funding are related in this way, how would you prefer your country to spend its 
resources, (give percentages totaling 100%): 
% by direct National funding 
% via EC funding 
8B. Please explain your reasons: 
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9. Did the project have added value with respect to: (multiple answers allowed) 
21 a) links with other EC programmes or policies 
0 i) energy 
21 ii) agriculture 
1 iii) communications 
6 iv other, please specify 
42 b) improvements in scientific cohesion in Europe 
29 c) improvements of scientific infrastructure 
10 i) at a National level 
33 ii) at a European level 
4 d) connection with the social ethical and legal issues in the use of 
Biotechnology 
10. Please list what, in your opinion, are the three most important outputs of your 
BRIDGE project: 
a) 
b) 
11. Finally, is there one important issue which you feel is not addressed by this 
questionnaire or is there any other information you would like to add? 
Thank you for your help in completing this questionnaire. 
Please return the completed questionnaire, as soon as possible and in any case 
before 10 March 1995, to: 
BRIDGE Evaluation Panel 
c/o Institute of Biotechnology 
ΕΤΗ Honggerberg, HPT 
CH-8093, Zurich 
Switzerland 
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Sub-Annex VIb2 
BRIDGE EVALUATION QUESTIONNAIRE 
FOR PARTNERS 
General instructions. Where questions require a "Yes" or "No" answer, please circle 
the chosen word. In all other cases where there are multiple choices, please tick above 
the line next to your answer. Some questions can have more than one answer. These 
are indicated. 
I . Personal and project details. 
1. Name and address: Responses were obtained from 262 individuals 
2. Contract number: 
3. Project title: 
4. Project area, tick one: 
N-Projects: 
18 A. Information infrastructure 
23 B. Enabling technologies 
57 C. Cellular Biology 
35 D. Pre-normative Research 
T- Projects: 
19 Tl Yeast Genome Sequencing 
20 T2 Molecular Identification of New Plant Genes 
16 T3 Lipases 
25 T4 Biotechnology of Lactic Acid Bacteria 
6 T5 High Resolution Automated Microbial Identification 
19 T6 Animal Cell Biotechnology 
14 T7 Factors Regulating Plant Cell Growth and Differentiation 
In these questionnaire Annexes, only numerical summation of the responses is given. 
Narrative and other comments are of necessity ommited. 
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Π. Initiation of the BRIDGE Programme. 
1A. Did you have any input into the formulation of the scientific objectives of the 
overall BRIDGE Programme? 
Yes 69 No 179 
IB. If yes, was this: 
38 a) Indirect, through national representatives 
29 b) Direct, through Commission staff 
16 c) Other, (please specify) 
ΙΠ. Setting up your contract proposal. 
1. How did you become aware of the BRIDGE call for proposals? 
11 a) through the Official Journal of the European Union 
57 b) through contact with DG XII staff 
60 c) through National Authorities or representatives 
11 d) through the scientific press 
188 e) through personal contact with other scientists 
5 f) other, please specify. 
2. Were you: 
15 a) the primary instigator of the proposal 
101 b) one of a group of existing collaborators 
104 c) invited to join a group assembled specifically to prepare a 
BRIDGE proposal 
29 d) Invited to join the group after the proposal had been substantially 
formulated 
3A. Did you make any new contacts during the process of setting up the project? 
Yes 205 No 51 
3B. If yes, were they: 
190 a) Academic 
85 b) Industrial 
c) please specify from which countries 
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4. In developing the contract proposal, did you find that the Programme 
requirements for a spread of participants from a number of Community countries 
was: 
87 
25 
141 
a) 
b) 
c) 
a help 
a hindrance 
neutral 
5. Did your home Institution, (Contracts Officer, Industrial Liaison Group or 
others), help in setting up the project? 
Yes 75 No 175 
6. What were your main motives in applying for BRIDGE funding? Please select 
three in order of importance, indicationg your choice, 1, 2 and 3. 
Access to funding 
Access to scientific expertise 
Access to technical expertise 
Prestige 
Limited National funding 
To establish a network for future collaboration 
For business reasons, ( partnerships, access to products, 
access to sales, marketintelligence, etc.) 
5 2 0 h) Other, please specify 
7. Has your BRIDGE funding: 
13 a) replaced earlier National funding 
66 b) been a stimulus to obtaining further National funding 
158 c) Supplemented National funding 
8A. Prior to the award of the BRIDGE funding did you carry out work related to this 
project? 
Yes 225 No 29 
1 
105 
41 
4 
2 
15 
52 
3 
2 
37 
81 
18 
1 
29 
54 
2 
3 
38 
47 
27 
17 
20 
48 
10 
a) 
b) 
c) 
d) 
e) 
f) 
g) 
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8B. If Yes, which of the following was the source of this funding? 
77 a) University or other intramural source 
139 b) National programme 
45 c) Industry 
12 d) Non-goverment/Charity/Private funding 
38 e) a European programme 
0 f) EUREKA 
3 g) other international programmes 
8 h) Other, please specify 
9A. Was the project, during its lifetime, co-ordinated with or related to other projects 
within your lab with funding from the above sources? 
Yes 182 No 71 
9B. If yes, indicate the relevant funding source 
10. During the period of this project, how many people in you laboratory, not funded 
by the BRIDGE project, were working on related areas? 
11. In which other EC Biotechnology Programmes have you participated: 
IV. Project Application and Award Procedures. 
1. How did you find the EC procedures for making an application for funding under 
BRIDGE? 
1 2 3 4 5 
Easy to follow 31 66 64 59 27 Difficult to follow 
Documents and Documents and 
information leaflets information leaflets 
clear ^Q ηγ ^\ 31 17 c l e a r unclear 
Warning of deadlines Warning of deadlines 
adequate 92 60 43 41 17 inadequate 
2. How did you find the project evaluation and selection procedures? 
1 2 3 4 5 
Quick 19 51 92 61 24 Slow 
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Transparent/easy to Obscure/difficult to 
follow is 3i 70 79 51 follow 
Adequate feedback Inadequate feedbac of 
of refereed information n 32 64 68 68 refereed information 
3. What is the single most important improvement which you would propose to the 
procedures of calling for, selecting and awarding project proposals? 
4A. Did you seek help from EC officials in preparing your proposal? 
Yes 73 No 176 
4B. If yes, Did this include: 
53 a) Clarification of procedures 
31 b) Clarification of documents 
24 c) Clarification of terminology 
22 d) Guidance on categories of research 
4 e) Other, please specify 
V. Personnel 
1A. Have personnel been recruited into your laboratory specifically for the project? 
Yes 189 No 65 
IB. If yes, indicate the number of staff hired in the following categories: 
48 a) from other projects in the lab 
140 b) from own country 
29 c) from other EC countries 
(name countries) 
19 d) from non-EC countries 
(name countries) 
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IC. Indicate the number of staff recruited to the project in your laboratory in the 
following categories: 
Scientific 
Technical 
Administrative 
2. How many staff were retained in permanent posts? 
VI. Inter-laboratory contacts. 
1A. Did you have collaborations with any of the partners before the project 
commenced? 
Yes 180 No 74 
IB. If yes, how many? 
2. Are you satisfied with the coordination of the project? 
1 2 3 4 5 
Satisfied 144 71 24 14 4 Not satisfied 
3. Was the co-operation between the partners, on average, easy or difficult? 
1 2 3 4 5 
Easy 99 94 38 17 6 Difficult 
4. For scores of 3 and above, was the difficulty focused on: 
28 a) one partner 
26 b) about half the partners 
12 c) essentially all the partners 
5. Were the problems largely: 
22 a) technical 
26 b) non-delivery of promised results 
32 c) administrative 
4 d) language 
16 e) personality 
13 f) other, please specify: 
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Any other comments: 
6. Did the transnational collaboration required by the EC facilitate or hinder the 
achievement of the scientific and technical goals? 
183 a) Facilitate 
9 b) Hinder 
65 c) No impact 
7A. Have you had collaborations with any of the partners before the project 
commenced? 
Yes 168 No 73 
7B. If yes, with how many? 
7C. Did they involve: 
19 a) Literature work, (reviews etc) 
95 b) Joint experiments 
126 c) exchange of materials 
117 d) exchange of data 
43 e) exchange of personnel 
12 f) training undergraduates 
37 g) training of PhDs 
22 h) training of post-docs 
8A. Are you or will you be continuing collaboration with any of the partners? 
Yes 224 No 27 
8B. If yes, with how many? 
8C. Would this collaboration have occurred if the project had not taken place? 
Yes 58 No 161 
9A. Did the project have results which were unexpected or could not have been 
predicted before the work started? 
Yes 194 No 56 
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9B. If yes were these results: 
128 a) scientific 
75 b) in the quality of inter-laboratory contacts 
90 c) in generating new academic contacts 
36 d) in generating new industrial contacts 
22 e) in generating intellectual property 
18 f) in generating new product opportunities 
5 g) other, (please specify) 
Vu. Post-Programme Considerations 
1A. Is research continuing in your laboratory on the topic of the BRIDGE 
Programme? 
Yes 226 No 29 
IB. If yes, please give the source of funding: 
70 a) University or other intramural source 
131 b) National programme 
47 c) Industry 
12 d) Non-Government/Charity/Private funding 
82 e) a European programme 
0 f) EUREKA 
3 g) an international programme 
15 h) Other, please specify 
2. Does the continuation project involve any of the same personnel? 
Yes 172 No 57 
3. Does the continuation project include any of the same collaborators? 
Yes 177 No 52 
4. Does the continuation project include any industrial collaborators? 
Yes 111 No 111 
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5. Has EC funding affected the development of your group and your activities by 
making National funding: 
99 a) easier to obtain 
6 b) harder to obtain 
144 c) unchanged in this respect 
6. Has EC funding affected the development of your group and your activities by 
making industrial projects: 
75 a) easier to develop or finance 
0 b) harder to develop or finance 
167 c) unchanged in these respects 
About 20% of proposals submitted to BRIDGE were funded, the average EC 
contribution being 0.77 million ECU per total project. In your opinion would it 
have been preferable to have: 
85 a) more projects, each receiving < 0.77 million ECU 
61 b) fewer projects, each receiving > 0.77 million ECU V.A. 1 ^ / f e w e r projects, W ~ W * * each. 
58 c) other, (please specify) 
8A. Several EC countries feel that they should reduce funding National programmes 
as funding via EC programmes increases. Assuming that EC and National 
funding are related in this way, how would you prefer your country to spend its 
resources, (give percentages totaling 100%): 
% by direct National funding 
% via EC funding 
8B. Please explain your reasons: 
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9. Did the project have added value with respect to: (multiple answers allowed) 
60 a) links with other EC programmes or policies 
2 i) energy 
69 ii) agriculture 
15 iii) communications 
18 iv) other, please specify 
206 b) improvements in scientific cohesion in Europe 
107 c) improvements of scientific infrastructure 
73 i) at a National level 
125 ii) at a European level 
34 d) connection with the social ethical and legal issues in the use of 
Biotechnology 
10. Please list what, in your opinion, are the three most important outputs of your 
BRIDGE project. 
a) 
b) 
c) 
11. Finally, is there one important issue which you feel is not addressed by this 
questionnaire or is there any other information you would like to add? 
Thank you for your help in completing this questionnaire. 
Please return the completed questionnaire, as soon as possible and in any case 
before 10 March 1995, to: 
BRIDGE Evaluation Panel 
c/o Institute of Biotechnology 
ΕΤΗ Honggerberg, HPT 
CH-8093, Zurich 
Switzerland 
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Sub-Annex Vic3 
BRIDGE EVALUATION QUESTIONNAIRE 
INDUSTRIAL ASSESSMENT OF BRIDGE ACTIVITIES 
General information. The term European Programme refers to a Biotechnology 
Programme within the Framework Programmes such as BAP, BEP or BRIDGE. 
Where questions require a "Yes" or "No" answer, please circle the chosen word. In 
all other cases where there are multiple choices, please tick above the line adjacent 
to your answer. 
The answers given in this questionnaire will be used collectively and will not be 
attributed to an individual or an organisation. Under these circumstances, would you 
be willing to have your name and affiliation stated in the Evaluation Panel's Report 
as a person who was consulted? 
Yes 30 No 7 
I . Personal details. 
1. Name: 
2. Position: 
3. Organisation: 
4. Address: 
Π. Awareness. 
1. Did your organisation participate in one or more of the projects carried out under 
the BRIDGE Programme? 
Yes 5 No 24 
2. Were you, or was your organisation aware of the BRIDGE Programme? 
Yes 24 No 4 
3 In these questionnaire Annexes, only numerical summation of the responses is given. 
Narrative and other comments are of necessity omitted. 
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3. Were you aware of European Biotechnology Programmes preceding BRIDGE, 
(i.e. prior to 1990)? 
Yes 18 No 11 
4. Are you aware of biotechnology programmes following BRIDGE, (i.e after 
1992/3)? 
Yes 26 No 3 
5. Are you interested in the biotechnology programmes of the European Union? 
1 2 3 4 5 
Very interested 17 5 5 0 2 Not interested 
6. Are you interested in the biotechnology programmes of your own country? 
1 2 3 4 5 
Very interested 21 4 1 1 2 Not interested 
ΙΠ. Future EU and National Biotechnology Programmes. 
1. How useful are government programmes for the development of a strong 
European biotechnology industry? 
National Programmes. 
1 2 3 4 5 
Very useful 8 12 8 1 0 Not useful 
EU Programmes. 
1 2 3 4 5 
Very useful „„ Not useful 
3 13 8 3 3 2 
2. How useful are government reseach programmes for your company? 
National Programmes. 
1 2 3 4 5 
Very useful 7 16 3 2 1 Not useful 
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EU Programmes. 
Very useful. .Not useful 
3. How do European programmes in biotechnology support the activities of your 
company? 
Directed by: Very 
Significant 
Not 
Significant 
Input into R&D activities 2 10 3 4 8 
Development of applications 2 3 2 11 10 
Patent development 1 2 3 7 15 
Indirectly by: 
Increased research in areas 
of interest to your company 4 13 6 3 1 
Integration of European 
research 9 8 3 3 4 
and scientific community 
4. Please indicate the significance of European programmes in biotechnology to 
your company, (1 = most important, 5 = least important): 
a. Development of European scientific community 
b. Development of European knowledge base 
c. precompetetive research 
d. strategic research 
e. development of specific products or processes 
5. What is your view of European and National expenditures for R&D programmes 
in biotechnology. (Give percentage changes you would like to see for higher or 
lower expenditures or tick for unchanged). 
1 
7 
4 
5 
7 
8 
2 
9 
12 
10 
6 
2 
3 
6 
6 
9 
6 
6 
4 
1 
3 
3 
5 
7 
5 
5 
3 
1 
1 
5 
National 
Expenditures should be % higher 
European 
Expenditures should be % higher 
unchanged 
unchanged 
% lower 
% lower 
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6. What proportion of the total government research expenditures in biotechnology 
should in your opinion be distributed through EU and National programmes? 
via European programmes % 
via National programmes % 
(totals must be 100%) 
IV. Non-participation in the BRIDGE Programme. 
1. . Please give the reasons why your company did not participate in the BRIDGE 
Programme. Multiple answers are permitted. 
a. Grants are too small 
b. Confidentiality problems 
c. Complexity of collaborating with academics 
■ d. Requirement for precompetetive research 
'."· e. Expecteation of limited pay-off 
f. Irrelevance of research areas in BRIDGE 
' g. Slowness or complexity of administration of the award system 
"·· h. Limited company funds 
' ■ i. Limited availability of specialised company manpower 
'"* j . Requirement for a transnational collaborative programme 
, Je. Other, please specify, 
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Annex VII 
Evaluation of the Programme Management 
Introduction 
BRIDGE was managed by the Biotechnology Unit (called "Division of Biotechnology" 
at the time) of DG XII. The Evaluation Panel collected information on management 
aspects from three main sources: 
1. Presentations by scientific officers of the Biotechnology Unit, covering essentially all 
aspects of the programme, an interview with Dr D. de Nettancourt (Head of the 
Biotechnology Unit when BRIDGE was launched), two presentations by Dr E. Magnien 
(the present Head of the Biotechnology Unit) and an interview with Mrs Soares, from 
the Administrative Sector, interviews with Mr. Hansen, Head of Life Sciences, DG XII, 
and other programme managers. 
2. The official documents and leaflets edited by DGXII and pertaining to BRIDGE 
(including the Final Report edited in 1994) that collectively give an official presentation 
of the programme as seen by its managers. 
3. Interviews and questionnaires from the coordinators and the participants of the various 
research projects. The scientific and the administrative aspects of these responses have 
been considerated elsewhere. 
SCIENTIFIC MANAGEMENT 
The Panel is happy to express its very positive judgment on the enthusiasm and the 
professional competence of the Managers of the Biotechnology Unit. The success of 
BRIDGE was to a large extent due to the dedication and sound judgement of the 
scientific officers in charge of the Programme. Interviews with the participants 
confirmed that contacts with the scientific officers in Brussels had generally been very 
satisfactory, especially for the reassuring feeling that the person "on the other side" was 
able to speak the same language as the researcher. It is important that this valuable team 
be kept at maximum efficiency, with aquisition of new skills, continuous updating of 
scientific information, and frequent dialogue with academia and. industry. Without 
wishing to diminish our good opinion of the Unit, the Panel therefore wishes to draw 
attention to areas in which problems were perceived in the role of DGXII. These include 
the initial planning of project areas, the format of the application procedures, and the 
way the scientific output of the programme was assessed by the scientific officers in 
charge. 
Role of DGXII in the initial planning 
The initial choice of research areas to be included in a programme has tremendous 
influence on the overall significance of the programme itself. It is not surprising that 
some national representatives, members of industry or individual scientists should have 
expressed criticism about the choice of BRIDGE topics. It is unfortunate, however, that 
there should be a general feeling that these decisions were taken somewhat arbitrarily, 
on the basis of obscure criteria and in response to ill-defined pressures. It is important 
that the initial process of topic selection be carried out with the utmost transparency, 
81 
clearly publicising the various inputs that concur to the final decision such as Council 
and Parliament mandate, Directorate guidelines, national representative input, expert 
panels, ad hoc investigations, industrial representatives and so on. 
Format of the application procedures 
A questionnaire sent to all participants showed that 57% (150/262) felt the application 
procedures were difficult to follow (rating them 3 or above on a 1 to 5 scale) with 10% 
giving the worst rating. A related question on the clarity of these procedures gave almost 
identical figures. Finally, 39% felt that warning on application deadlines was inadequate. 
The same questions were addressed to project coordinators, who had a closer contact 
with DGXII, and the figures were not very different (50 %, 38 % and 42 % respectively). 
In summary, applying to BRIDGE appeared to be an unduly complicated affair. The 
complexity of the application forms must have been recognised, since these forms are 
more streamlined in the present Biotech programmes. Whether this really simplified the 
situation for the applicants remains to be seen. 
Scientific assessement of the Programme by the Biotechnology Unit 
The Biotechnology Unit is facing a difficult task in assessing the scientific output of a 
Programme like BRIDGE. On the one hand, a substantial effort had to be made in 
presenting the results of BRIDGE to the general public, an important endeavour in view 
of the some apprehension about biotechnology. Most of the numerous leaflets that were 
published on various BRIDGE topics were clear, informative and attractively edited. 
Little evidence is available about the efficiency of dissemination of such material. On 
the other hand, the Unit has to be aware of the scientific or industrial shortcomings of 
the Programme (and of individual contracts) as well as of its successes, and must be 
well-informed of the latest scientific and technical progress to encourage innovative 
research. 
Documents produced for public relations purposes are of little use for scientific 
evaluation. This could be one of the main functions of the Final Report which was, 
however, inadequate in several respects. It attempted to organise individual reports into 
a standard format with five sections (Background/ Objectives and primary approaches/ 
Results and Discussion/ Major scientific breakthroughs/ Major cooperative links), but 
the length of these contributions was very heterogeneous between different reports. For 
example, one network took 7 figures and 18 pages to present its results, whilst listing 
only two publications and one paper presented in a national symposium, which indicated 
a rather modest scientific output. The format of these reports could be simplified, for 
example by merging Results, Breakthroughs and possibly Cooperative Links into a single 
section that gives the main results of the contract, and by specifying a strict maximum 
length. 
The publication lists did not discriminate between the quality of the various references 
and were consequently very difficult to use for scientific evaluation. They mixed genuine 
publications in refereed journals or international symposia with congress abstracts and 
papers in obscure journals, (in one report, the list of publications was limited to three 
papers in a little-known Hungarian journal), contributions to symposia organised by the 
BRIDGE programme itself (quite abundant in some reports), papers submitted for 
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publication and even numerous manuscripts "in preparation". References were pooled 
in a way that made it quite difficult to identify individual contractors and, in some 
reports, the lack of titles did not allow a check of whether they were actually relevant 
to the contract. Additional editorial effort is needed to turn the Final Report into a more 
useful reference document, both for internal DG XII use, for external presentation to the 
scientific community and for independent Programme evaluation. 
The 11 scientific officers of the Biotechnology Unit all have PhDs or equivalent 
academic titles, and several of them were active post-doctoral scientists before joining 
the EU administration. However, their main link with active science will inevitably be 
through their contractors and scientific advisers. Indeed, the personal commitment of 
some scientific officers to the projects they had in charge was quite perceptible. This 
may lead to a biased view of the quality of European-funded projects as opposed to 
similar research elsewhere (including in Europe). Really mediocre science will generally 
be recognized as such, but there is a risk of encouraging self-perpetuating scientific 
"clubs", whereas small innovative teams may have difficulty to be included in 
transnational networks. 
T-projects deserve special scrutiny in this respect, because of the large sums involved, 
the number of participants (which has grown to more than 100 in recent Biotech 
framework programmes), the fact that most of these projects went on in subsequent 
Framework Programmes and finally, the considerable responsibility and power of the 
coordinators of such projects. There will inevitably be a tendency to delegate part of the 
necesseray controls from DG XII to the coordinators themselves, which has obvious 
advantages in terms of management, but is not without risks. The Panel knows of no 
serious problem related to this situation as far as BRIDGE was concerned, but is aware 
that this is a somewhat controversial issue in the European scientific community. 
The staff of the Biotechnology Unit is well aware of these problems, and should be 
encouraged to find appropriate solutions. Several suggestions can be made at this point. 
They include more opportunity for scientific officers to attend international meetings (in 
addition to the internal symposia organized within BRIDGE-funded networks), sabbatical 
stays in research institutions or industry, individual visits to laboratories. T-projects 
should be evaluated by independent scientific committees making recommendations as 
to the renewal or future evolution of these projects. Devices should be found to support 
small innovative teams (i.e. young group leaders and possibly alleviating the requirement 
for multinational participation). 
ADMINISTRATIVE MANAGEMENT 
The Administrative Sector of DGXII took care of the voluminous procedures involved 
with the disbursement and the accounting of BRIDGE funds. With the continuing 
expansion of the sums involved and of the number of contractors, this demanding task 
deserves full appreciation from the scientific community. A questionnaire directed to 
a sample of industrial laboratories that did not participate in BRIDGE indicated 
"slowness or complexity of administration of the award system" as the most frequent 
reason for non-participation (quoted in 16/37 responses). There was also anecdotal 
evidence on this issue in the interviews of individual contractors. Some of these 
criticisms should be taken cum grano salis, the European administration being a 
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convenient scapegoat for the sins of local administrations. Indeed, when BRIDGE 
coordinators were asked whether they were satisfied with the help received from the EU 
management in administering the project, their answer was fairly positive (33/52 rating 
< 3 i.e. good to satisfactory). Coordinators also gave a generally favourable judgement 
on the handling of fund distribution (36/52 positive answers). Nevertheless, the Panel 
believes that some real problems emerged about the complexity of procedures and the 
slowness of payments. Moreover, the fragmentation of research funding between 
consecutive programmes appears to have serious managerial drawbacks. 
Complexity and slowness of procedures 
This is probably one of the most common complaints about EU research programs. Yet, 
when the Panel attempted to explore the administrative procedures, little was found that 
could be drastically simplified. In fact, some aspects such as the accounting requirements 
could be reasonably classified as quite liberal. An almost automatic doubling of 
complexity is due to the fact that funds are disbursed to project coordinators and then 
subdivided to all participants. This is unavoidable if the Brussels administration is unable 
to deal with each single contractor. Complaints about the slowness of procedures are 
obviously linked to the previous ones in a cause-effect relationship. However, this is 
more easily quantifiable, since the time elapsed between launching of BRIDGE (call for 
proposals) and implementation (initial payments) was of the order of one year or more. 
Much of this time (about six months) was taken by the project selection procedure. It 
is disturbing to see that the evaluation by scientific experts, which is the key step in this 
process, took only about one month. As far as the Panel could see, the rest of the time 
was spent in complicated in-house reviewing procedures involving discussions by CAN-
Bridge, inter-Directorate reviewing and information to the Director General and his 
Cabinet. It is hard to believe that this lengthy process is really necessary as far as project 
selection is concerned. Indeed, it would be rather surprising if the priority list produced 
by scientific experts was revised by the DG XII management (the Panel has been told 
that this happened only in very exceptional cases, but there were apparently cases where 
the amount of money allocated to given contracts was substantially reduced with little 
or no explanation). The Panel firmly believes that drastically reducing the time spent on 
in-house reviewing would be a notable improvement in the management of EU research 
programmes. 
Continuity of Infrastructure Projects. 
The BRIDGE Programme has supported a number of projects that contribute to the 
infrastructure supporting biotechnology research and development, in particular a series 
of N-projects that are reviewed elsewhere. These activities are currently supported by 
funds from competitive applications. This mechanism of support does not make sense 
when applied to Infrastructure projects. Such projects may involve for example setting 
up a data base or a culture collection. Once the project is over, if further funding is not 
forthcoming, the data base will become derelict or the culture collection die out. The 
initial funding will have been wasted and the service is not easily reinstated. 
Such projects may be started by competitive tender, but they need secure funds for the 
maintenance of the service and to keep it up to date. Obviously performance should be 
reviewed periodically and the review could include a further element of competitive 
tender. A mechanism should be devised to ensure that valuable infrastructure services 
are not dependent on competitive funding for their maintenance. 
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Conclusions & recommendations 
1. The scientific management was carried out by a remarkably competent and dedicated 
team. It is important that the scientific competence of programme managers be 
maintained at the highest level by continuous cultural updating and by frequent 
exchanges with the "outside" academic and industrial community. 
2. Efforts should be made to increase the transparency of the programme planning 
mechanisms that lead to the topics selected for inclusion in the proramme. 
3. A more careful editing of the Final Report is needed to make it a useful scientific 
evaluation tool and to document the scientific credibility of the Programme. 
4. Attention should be directed to the simplification of intra- and inter-Directorate 
procedures that contribute to the slow administrative process in the project selection 
procedure and lead to an unacceptable time lag between project selection and the first 
payments. 
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Annex Vul 
Evaluation of the Training Activities 
1 Summary of activities 
1.1. The training programme amounted to about 7 MECU (7% of the total Bridge 
programme), with 6.2 MECU for fellowships and 0.4 MECU for Workshops. The 
proportion of funds allocated to training activities, relative to the total framework 
programme, was substantially higher under the previous BEP (21%) and BAP (9%) 
programmes but has been unchanged or slightly reduced in subsequent Biotechnology 
programmes. 
1.2. One hundred and sixty nine fellowships were granted out of 552 applications, (29 %). 
In addition, 42 fellowships were awarded from the "European Postgraduate Training 
Network" (see below, 1.7). There were three types of grants: 
90 fellowships of "category 20", for post-graduates (applicants with a University 
degree) with at least one publication in a peer-reviewed journal. 
63 fellowships of "category 30", for applicants with a PhD degree (or more than 
2 years postgraduate research experience) and at least four publications. 
Applicants with the degree or the experience of "category 30" but with less than 
the requested 4 publications could still be awarded a "category 20". About a 
quarter of the "category 20" trainees belonged to that subclass. 
9 fellowships of "category 40". These are short term fellowships (less than 6 
months), for established researchers visiting another laboratory of the EU to learn 
or practice specific techniques. 
Travel expenses were covered by the fellowships. 
1.3. Laboratories hosting a category 20 trainee received bench fees of 5 kECU. Category 
30 trainees included 10 kECU Bench fees. Bench fees are not mentioned in the 92-94 
Information Package for Training Grants but a contribution towards host laboratory 
expenses, which will be only partial, is mentioned in the 94-98 package. 
1.4. Categories 20 and 30 fellowships could not exceed 24 months. In practice, all but 
one of the requests were limited to 18 months because the funds available would have 
otherwise limited the total number of fellowships granted. In addition, 43 fellowships 
were awarded for one year and 12 for six months or less. 
1.5. Most trainees were from France, Italy, Spain, Germany, Greece and Belgium, with 
the United Kingdom and, to a lesser extent, France, Germany and the Netherlands 
contributing most of the host laboratories. This shows a tendency towards the spread of 
expertise from more northern to more southern countries by the training programme. 
1.6 The selection procedure for BRIDGE training grants was rather unusual being carried 
out entirely in Brussels by a committee of two scientific delegates elected in a plenary 
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session of the CRN-Biotechnology, plus the head of the Biotechnology Unit. A new 
procedure, developed for Biotechnology 92-94 and 94-98, is described below (paragraph 
3.5). 
1.7. The European Postgraduate Training Network, a special postgraduate training 
programme was targeted to a network of 59 laboratories working in the area of Genetic 
Engineering & Molecular Biology of Seed Improvement. It was operated by the Dept of 
Physiology, Carlsberg laboratory (Prof. D. von Wettstein). Forty-two fellows (all external 
to the network) were selected from 81 applicants to work in 16 host institutions belonging 
to the network. The geographic distribution of host laboratories was quite skewed, with 
the United Kingdom (18) and Denmark (9) providing half of the host laboratories. This 
experiment has not been repeated, although one large project in Biotechnology FPIII had 
an internal training scheme. 
1.8 There were 9 two-week workshops with a mixture of practical courses and lectures, 
mostly directed to the training of young scientists. They were held in scientifically less 
strong European countries, to facilitate the participation of local scientists. The average 
funding by the commission was of about 40 kECU per workshop. 
2 Major changes since the completion of BRIDGE 
Since the completion of BRIDGE there seem to have been fewer fellowships and an 
unchanged financial input. According to the 94-95 information document on Research 
Training Grants, the budget of the FPIV training programme for biotechnology has 
increased roughly by a factor of 5 (33 MECU) when compared to Bridge, thus remaining 
more or less in the same proportion with respect to total biotechnology funds (7%). 
However, the total number of fellowships foreseen (estimated at about 350), would be less 
than half those expected by extrapolating the number awarded under Bridge (211). This 
lower output in terms of fellowship number is a very negative trend. Its sources are 
apparently multiple. On the one hand, fellowships are more expensive due to adjustments 
for inflation, and, because they are now treated as grants, they are liable to taxation. On 
the other hand, a new type of "R" fellowships was introduced. These one-year re-entry 
grants are reserved for researchers that held a post-doctoral fellowship of "category 30" 
and undertake to return to "less-favoured" regions as defined by the Council of Ministers. 
The definition of categories 20 and 30 of fellowships became more restrictive under 
Biotechnology FPIII, since candidates with a PhD but with less than 4 publications were 
no longer covered by "category 20". Under Biotechnology FPIV, "category 20" was 
extended to graduates with up to 4 years of experience and at least one publication. A 
PhD with less than 4 publications will remain excluded from the training programme. 
According to the FPIV Information Package, a commitment letter is sent to all selected 
applicants within four months after the submission deadline (rejection notices are given 
within two months). Upon signature of the contract by the Commission, applicants have 
six months to start their activities. 
3. Comments 
3.1. The training programme was a successful and very important component of 
BRIDGE, especially with regard to fellowships. Allocating fellowships to young and 
promising scientists is a simple and effective way of promoting a European science 
community, supporting good quality science in the technically less advanced countries and 
encouraging technology transfer. The capacity to attract young scientists is in itself a sign 
that the host laboratories are scientifically productive. All this contributed to building a 
wider cultural community amongst European scientists. 
3.2. The percentage of programme budget allocated to these activities continues to show 
a decreasing trend. Concomitantly, the success rate of applications has decreased, while 
there is no indication that their quality deteriorated. Moreover, according to the FPIV 
information document on Research Training Grants, about 350 fellowships might be 
granted, i.e. half what would have been expected by extrapolating from the 211 
fellowships awarded under Bridge, since the overall budget was multiplied by five. 
3.3. The cut to 18 months in the maximum duration of all fellowships is unfortunate. This 
is too short for a young and relatively inexperienced researcher in a new environment to 
produce optimal results. Curiously, European training grants can be extended to 3 years 
in various other disciplines, but are "strictly limited" to 24 months in biotechnology. 
3.4. A system of short-term fellowships (ranging from a few weeks to three months and 
accessible to any pre- or post-doctoral scientist) would probably be one of the more 
efficient and cost-effective way of promoting human mobility in this rapidly expanding 
and evolving high technology field. 
3.5. The selection procedure initially used under Bridge was replaced by a procedure 
primarily based on written evaluation from external experts who are explicitly instructed 
to rely entirely on scientific criteria. The Panel views this as a very positive change. The 
role of the in-house selection committee was apparently limited to ranking applicants 
according to the referees judgement, adapting the scores when serious discrepancies 
appeared between referees and possibly redressing unjustifiable biases in terms of 
geographic distribution. This pre-eminence of scientific quality in the selection procedure 
is crucial to the credibility of European training grants. The list of evaluators was not 
disclosed, even to this Panel. Individual evaluators of a given application must of course 
remain anonymous, but a regular release of the list of evaluators would document their 
competence and would increase the credibility of the system. The panel regrets that it can 
make no judgement on the scientific competence and general reliability of these experts. 
3.6. The difference in the amount of bench fees paid under Bridge to laboratories hosting 
category 30 versus category 20 trainees is unjustifiable. Bench fees are an important 
aspect of training fellowships and should be maintained at the level used in Bridge for 
category 30 fellowships. 
3.7. The publication criteria for category 30 (4 publications, preferably as first author) 
is very stringent and probably eliminates a large proportion of new PhDs at a time in their 
careers when they are most flexible and able to benefit from working in another country. 
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3.8. The 42 fellowships awarded under the European Postgraduate Training Network 
were considered as an experiment by the Bridge planners. The Panel was unable to collect 
unequivocal evidence to decide whether this was a success or not. Given the sizeable 
amount of resources taken up by this sub-programme (about a quarter of the normal 
Bridge fellowships) and the possible problems connected with any exception to general 
procedures, it is probably best to reserve such special initiatives to exceptional cases. 
3.9. The small number (nine) of Advanced Workshops held under Bridge covered 
reasonably important subjects and thus presumably contributed to strengthen European 
expertise in Biotechnology. However, the Panel made no specific attempt to scrutinise the 
scientific quality and relevance of these workshops. 
4. Recommendations 
The importance of training programmes is often overlooked in favour of more visible 
research funding. Yet, this is a most effective way to disseminate technical know-how and 
to support active laboratories capable of attracting young scientists. We strongly 
recommend that the financial priority given to the training fellowship programme be 
higher than in the past. We endorse the doubling in size (about 15% of the total budget 
of biotechnology programmes) already recommended for Bridge by the BEP-BAP 
Evaluation Panel, and regret that this recommendation remained largely ignored. We are 
particularly worried by current projections indicating a two-fold reduction in the number 
of fellowships allocated per unit cost. 
The Panel believes that the training programme was handled in a fair, competent and 
efficient way. We recommend the following measures to improve its efficiency: 
1. Introduce a system of short-term fellowships (less than 3 months), to increase the 
flexibility of the current training system and its capacity to promote the fast dissemination 
of new techniques. 
2. Revise the upper limit of 24 months for long-term fellowships. The possibility of a 
third-year extension should be preserved. 
3. Revise the strict requirement for four publications in the case of category 30, which 
discriminates against fresh PhD holders. 
4. Release the list of the evaluators at regular intervals, as a tribute to their work but also 
to document their general competence. The strict secrecy of DGXII in this regard is 
detrimental to the credibility of the selection process. 
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5. Documents consulted 
Bridge: Draft report on the training grants. Internal document prepared by DGXII (14 pp. 
January 1995). 
European Postgraduate Training Network: application of genetic engineering and 
molecular biology for seed improvement. DG XII, Division Biotechnology, 18 pp. 
(undated) 
Information Package on Research Training Grants (edition 1994-1995) 
List and summary description of the nine advanced workshops supported by the Bridge 
training programme. 
The Panel had a presentation of the training programme by Dr A. Vassaroti (6 February, 
1995), and a 40 min interview with him on the same topic (Apr. 4, 1995). Three letters 
were also written by Drs A. Vassaroti and E. Magnien in response to specific points 
raised by the Panel on the training programme. 
Finally, the Panel examined the recommendations on the training programme made by the 
evaluation Panel of the previous biotechnology framework programmes BEP and BAP. 
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Annex IX 
Evaluation of the Concertation Actions 
Introduction 
The inclusion of concertation actions in the BRIDGE programme was based on the 
Council Decision of 27 November 1989. Concertation was integrated quite early into the 
European Biotechnology Programmes as a response to the rapid development of new 
technologies involving both the biological sciences and engineering. Since the field has 
high economic potential, but is also open to much misunderstanding and criticism, 
Concertation was initiated to network the information dissemination activities, both 
within the Commission and publicly to ensure a constant flow of information. 
The evaluation has to consider whether the programme has in fact implemented the task 
specified in the Council decision. 
Accomplishments 
Concertation was supported by a budget of 4.6 MECU. There were four main tasks 
required by the Council decision. These were: 
1. Monitoring, assessing, and informing. To monitor developments in Biotechnology 
particularly in research and technology development (RTD) and to assess their impact 
on social and economic aspects. Commission services and national and public authorities 
could use this information to implement policy and make decisions on future 
programmes. 
The main output has been the launching of the European Biotechnology Information 
Service (EBIS) in paper and electronic form generating a mailing list of about 7000. In 
addition a number of reports and studies on different topics related to the programmes 
were compiled. A series of information meetings, that aided in the monitoring and 
assessment of programmes, took place. 
2. Contextual conditions, effectiveness, coherence, international collaboration. The 
Council decision stated the main objectives as "Identifying possible ways in which the 
contextual conditions for the beneficial development of biotechnology in Europe may be 
improved, and the effectiveness and coherence of Member State and Community 
biotechnology programmes and related policies enhanced, including those involving 
international collaboration". 
This targets internal services of the Commission as well as external institutions. One 
result was the creation by the Commission of the high level inter service Biotechnology 
Coordination Committee (BCC). Other activities were supported, for example, meetings 
for European students and alumni and providing an on-line inventory of publicly-funded 
biotechnology research projects in Europe. Intellectual property was recognised as an 
important component of these activities, however, this was transferred to another unit 
(Legal and Ethical Aspects of Life Sciences and Technologies). 
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(8) 
3. Disseminating knowledge, increasing public awareness. The Council decision included 
"Disseminating knowledge and helping to increase public awareness and understanding 
of the nature, potential and possible risks associated with biotechnology". 
A survey was financed in 1991 and 1993 called Eurobarometer. This was designed to 
identify trends in public opinion on biotechnology and genetic engineering. 
4. Identifying needs and promoting greater SME activity. The Council decision was: 
":..to promote greater activity in the biotechnology small-firm sector in the 
Community". 
The aim was to reinforce the biotechnology component within existing initiatives of the 
Commission for the support of SME's. Prominent Commission programmes were 
SPRINT and VALUE. Training initiatives were also included. 
Evaluation 
Concertation activities were run by CUBE (Concertation Unit for Biotechnology in 
Europe) until September 1992. Our interviews indicated that CUBE performed an 
important function and we confirmed its overall effectiveness prior to the reorganisation. 
In September 1992 a reorganisation took place which disrupted its function. Concertation 
tasks were continued outside the framework of the Unit with the following results. 
For task 1 our findings indicate that the residual function was one of information. This 
was a direct consequence of the closure of CUBE which resulted in limited human 
resources to carry out effective monitoring and assessment. It is not clear that these 
services are widely used. 
The emphasis in task 12 appeared to favour external initiatives (addressed to Member 
States) rather than activities within the Commission. Included were the dissemination to 
all services of information about BCC activities and the secretarial support to the 
members of DG XII attending the meetings of BCC. CUBE also played a role in the 
discussions of regulatory and intellectual property issues although the results in this area 
have not been entirely satisfactory. 
The main effort in task 3 has been to develop means to assist the public understanding 
of biotechnology. Significant progress has been demonstrated in this field. However, 
there were some limitations. Member states varied in the degree in which they used this 
activity. This may have resulted in a missed opportunity to use the full authority of 
Commission bodies. 
In spite of the importance of task 4 the outcome has been inadequate. Reports and 
publicity are not sufficient to entice small firms to participate in programmes. 
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Recommendation 
Concertation actions continue to be required but should be focused on specific audience 
needs. 
Reports to busy executives, administrators, Members of the European Parliament and 
other policy makers and opinion formers, should be very concise and user friendly. 
It is particularly important to explain the role of risk assessment in relation to such issues 
as the Deliberate Release of genetically modified organisms to ensure that reliable 
scientific knowledge is available to those involved in making judgements about ethical 
and legal issues. 
Intellectual property issues require special attention to ensure that decisions are made on 
the basis of scientific knowledge and with full regard to international competition. 
Decisions on ethical issues in this area are equally in need of a full information base. 
Programmes must take full account of the need to inform the public about scientific 
issues, their benefits, and possible disadvantages, so that informed judgements can be 
made. 
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Annex Χ 
A survey of R&D spending by National Governments and the EU 
The European Community of 12 member states until 1994, and the present EU of 15 
member states, spends public funds on R&D via the National governments, and via the 
EC/EU Framework Programmes. According to the European Report on Science and 
Technology Indicators 1994 (Report EUR 15897 EN, October 1994, produced by 
DGXII), total government R&D spending via National governments has increased from 
31 billion ECU in 1984 to 50.3 BECU in 1993. This is based on current prices and 
current exchange rates from national currencies to ECUs for each year and is not 
corrected for inflation or exchange rate fluctuations and currency devaluations. During 
the same period, the budget component reserved by the European Commission for R&D 
increased from 0.44 BECU to 1.95 BECU. For the period 1994-1998, a further increase 
will be seen, with yearly spending for R&D via the FPIV in excess of 3 BECU. 
The percentage of EC funding versus aggregate National government funding for R&D 
has increased in the past decade, from 1.5% in 1984, to 4% in 1993, and should reach 
6-7% in 1994-1998. There is room for further growth after 1998, since R&D funds 
allocated by the EC will amount to only about 4% of the total EC budget of 75 - 80 
BECU per year for 1994-1998. 
Allocation of R&D funds at the National and European levels 
The allocation of R&D funds by National governments and the EC differs considerably, 
thereby introducing large variations in the impact of EC R&D programmes on National 
R&D activities. For the aggregate National governments, major R&D allocations are 
made for Defence (about 10 BECU per year from 1988 to 1993, or more than 20% of 
the total National R&D budgets) and space research (about 2.5-3.5 BECU from 1988 
to 1993, or more than 6% of National R&D). In these same areas, the EC has allocated 
no funds to Defence, and a decreasing amount of only 25 to 8 MECU from 1988 to 
1993, or 2.5-0.3% of total EC R&D funds, for space research. 
Another major component of National R&D spending not seen at the EU level is 
Research from General University funds (about 9.1-13.6 BECU from 1988 to 1993, or 
22-27% of total National R&D spending). Free Research (4.8-7.1 BECU from 1988 to 
1993, or 13-14% of National R&D), has lately been supported by EC funding, going 
from 24 MECU in 1988 to 285 MECU in 1993, or increasing from 2.5% to 14% of 
total EC R&D spending. 
Thus, about half of National governmental R&D funding is devoted to areas in which 
there is no EC R&D spending: Defence (about 20%), Space (about 6%), and Research 
from General University funds (about 25%). 
EU funds for specific R&D Programme will average 12% in 1994-1998 
EC funds for R&D are used in specific areas, which are often also supported by 
National government programmes. Since all of the available EC funds (more than 
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3 BECU per year from 1994-1998) are used for such specific areas, while only half of 
the National funds (about 25 BECU per year in the same period) will be available for 
these same areas, the EC contribution to specific National R&D programmes will be 
12% on the average. 
R&D expenditures by National governments 
There are significant differences among the European member countries in total and per 
capita R&D spending by National governments. Taking the decade from 1984 to 1993, 
and based on current prices and current exchange rates from national currencies to ECUs 
for each year, Germany, France, Italy, and Spain have doubled (or in the case of Spain, 
even tripled) their spending on biotechnology and other R&D programs, and increased 
their total percentages of GNP allotted to R&D. In the same period, spending in the 
Netherlands increased by only 60%. Remarkably, in Great Britain total government 
R&D expenditures in current ECUs remained constant during the past decade, which 
implies a decrease in British R&D funding equivalent to the cumulative inflation in the 
past decade. 
Taking total National government expenditures on R&D in 1993, Germany and France 
now account for about 31 % and 27% respectively, of all National R&D expenditures in 
the EU. Italy and Great Britain each account for about 11-12% ; Sweden, Spain, and the 
Netherlands each account for about 4%; Belgium, Austria, Finland and Denmark each 
account for 1.5-2.1%; and Ireland, Portugal and Greece each spend 0.4-0.7% of total 
R&D funds available from National governments in the EU. 
The contribution of FPIV spending to European R&D spending in 1994-1998 
The FPIV contribution of the EU to total government R&D spending in 1994-1998 will 
be of the order of 6-7% of total National spending. However, since National government 
funding includes all government funding via Universities, Institutes and Industry 
(especially in the Defence area), the impact of the FPIV programme will average 12% 
in those areas which the programme focuses on, such as Biotechnology, Environmental 
Sciences and Human Health. 
The EC/EU contribution to biotechnology research in Europe 
The EU contribution to biotechnology research has grown considerably in the past 
decade. The BRIDGE Programme entailed total expenditures of about 100 MECU, and 
the subsequent FPIII Biotechnology Programme distributed about 170 MECU, which 
represented a modest addition to National programmes. 
From 1994 to 1998, the FPIV programme will distribute 550 MECU for Biotechnology, 
as well as significant funds in related areas (680 MECU for Agriculture and Fisheries 
related projects, 340 MECU for Biomedicine and Health, and 850 MECU for 
Environment and Climate). This can be compared to the total spending on biotechnology 
programs by National governments. The National governments of the expanded EU 
(including Austria, Finland and Sweden) have distributed totals of about 2,000, 2,300, 
and 1,300 MECU per year in 1992 and 1993 for Agriculture, Human Health, and 
Environment, respectively. It is perhaps not possible to compare these amounts directly, 
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since they may involve differing definitions of the research areas covered. However, 
they provide a general indication of the level of EU versus National funding in the areas 
listed. To compare European and National expenditures, European expenditures for 
Biotechnology (550 MECU) and Biomedicine and Health (340 MECU) for 4 years are 
therefore compared to total National expenditures in Human Health of about 2,400 per 
year for the next few years, in which case yearly European spending in the general area 
of Biotechnology and Human Health accounts for about 9% of total National spending. 
Looking at total spending on Environment, Agriculture and Human Health 
(including Biotechnology), yearly European spending during FPIV will amount to about 
10% of total National government spending. 
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Annex XI 
Evaluation of the relationship of COST Activities to BRIDGE 
Introduction 
The COST (Cooperation Scientifique et Technique) Programme represents the oldest 
instrument for putting into practice the cooperation in science and technology in Europe. 
It was established at the beginning of the nineteen sixties by a European Community of 
six countries along with the thirteen EFTA countries. 
Main Characteristics 
1. The COST Programme matches the classical scheme of international scientific 
cooperation. The activities were developed through concertation mechanisms. Research 
activities from the participants were financed from internal sources, i.e. National funds, 
whereas the European Commission allocated COST funds to finance the sharing of 
scientific knowledge through scientific meetings, workshops, short-term exchanges and 
visits of scientists. 
COST was a forerunner of European networking in science and technology and continues 
to contribute to this activity. 
2. The States contribute to the COST Programmes through agreements from their 
respective Foreign Affairs Ministries. 
3. The COST Programme is managed through a Senior Officials Committee (SOC), with 
representatives from the countries and a Chairman and a Vice-chairman elected by them. 
The Secretariat of the SOC is part of the Council Secretariat. The Commission organized 
the horizontal support of the COST Programme through DGXII, providing specific 
support from the Programme Managers in cases where there was a specific relationship 
to the R&D Programmes. COST actions in Biotechnology Area related to the BRIDGE 
Programme are listed at the end of this Annex. 
4. COST actions arise and are run "bottom-up". Scientists from a given member country 
of COST propose topics of interest. The SOC approves an action, a Memorandum of 
Understanding is signed and a Management Committee for the specific action is agreed. 
This Management Committee is composed of scientists, representing the participating 
countries. 
5. The COST Programme has served to facilitate the incorporation of non-member 
countries into European research. It is becoming a good way to encourage the 
participation of laboratories from Central and Eastern Europe to R&D activities of the 
EU. In this respect, it must complement or overlap with other Programmes such as 
"RTD initiatives for the specific programme of cooperation with third countries and 
international organizations" 
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General Assessment 
Our findings show that the integration of COST activities with the objectives and 
management of the BRIDGE Programme presented difficulties. 
In many areas, COST actions have been at the origin of programmes that were 
eventually incorporated into the RTD Framework. This was the case for Agro-food 
(Eclair and Flair), Transport and, in part, Telecommunications. But this has not been 
the case for Biotechnology, the onset and incorporation of which into the Framework 
Programme derived from prospective analysis (FAST programme). 
It therefore seems likely that the difficulties in integrating COST actions into BRIDGE 
resulted from the lack of a tradition of COST activities in the field of biotechnology. 
Biotechnology programmes and the Biotechnology Unit were built and managed without 
a previous reference to COST activities. 
Specific assessments 
From the reports published on the COST activities associated with BRIDGE, several 
conclusions can be drawn. 
COST actions appeared to be complementary to the main objectives of BRIDGE in that 
they focused on agricultura and animal health issues. 
COST actions involved a high number of institutions and countries. The objective of 
fostering cooperation, a main aim of COST schemes, seems to have been attained quite 
satisfactorily. 
The ratio between the expenditures on BRIDGE and COST actions is such as to suggest 
a high added value of the COST activities. 
The leadership and strong participation from laboratories and researchers of the EFTA 
countries in the BRIDGE COST actions provided good grounds for the later integration 
of these countries and their laboratories into European Biotechnology RTD programmes. 
There was an excessive selection of topics with little potential for future application, 
probably resulting from the fact that the proposals were bottom-up with scant industry 
participation. 
Recommendations 
The COST schemes should be maintained provided that the aims and methods of 
implementing their actions is fully specified. 
The potential for applications arising from COST proposals should be highlighted since 
they may help to develop future roads within the programmes of the Life Sciences 
Division. 
The applied orientation of FPIV in Biomedical and Agriculture and Fisheries Research 
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may help to integrate COST actions into the new Programmes. 
The potential for a leadership role of research institutions from non-European countries 
that are members of COST should be stimulated. 
The potential for COST to provide a platform for the collaborative participation of 
laboratories from Eastern and Central European countries with those in the EU should 
be encouraged. Good coordination with other Programmes and Activities within the EU 
(i.e. RTD for third countries, PECO, PHARE) is needed. 
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List of COST actions 
Action 48. "Aquatic primary biomass-marine microalgae" 
Duration: 1985-1989 (first phase) 
1990-1994 (second phase) 
Financing: Total/10 years: 13.25 MECU 
National/10 years: 12 MECU 
CEC/10 years: 1.25 MECU 
Action 87. 'Plant in vitro culture" 
Duration: 1983 start 
incorporated in BAP 
incorporated in BRIDGE 
Financing: Total/10 years: 10 MECU+15 MECU= 25 MECU 
National/10 years 25 
CEC: not available, probably 1.25 MECU 
Action 88. "Methods of Early Detection and Identification of Plant Diseases" 
Duration: 1987-1993 
Financing: 3 MECU 
CEC: 3 MECU 
Action 89. "Basic research on coccidioses of poultry and farm animals and 
development of vaccines using biotechnological procedures" 
Duration: 1990(1989)-1993(1994) 
Financing: Total 8.4 MECU 
BRIDGE: 0.250 MECU 
Action 810. "Vesicular-arbuscular mycorrhizae" 
Duration: 1990-1994, 1994-1998 (COST 8.21) 
Note: The numbering of COST actions is as follows: the first digit designates a major 
sector, (4 represent Oceanography, 8 Agrofood). The subsequent digits indicate the age 
of the action, lower numbers indicating and an earlier time of initiation. 
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A panel of seven experts was entrusted with the task of evaluating the EC BRIDGE 
Programme (1990-1994). 
The panel was chaired by Professor Paul Christou. The panel met in Brussels on seven 
occasions between December 22nd, 1994 and July 11th, 1995. The major instruments 
for the evaluation methodology were a series of questionnaires (to programme 
participants, project coordinators and industrial leaders from non-participating countries), 
personal interviews and a study of selected programme reports and publications. 
The final report is divided into two parts: the first part includes the Executive summary 
and the Principal recommendations; the second part includes, among others, the 
evaluation of the projects by programme area, the main findings of the questionnaire 
surveys, the evaluation of programme management, training activities, concertation 
actions and BRIDGE-COST activities. 



Venta · Salg · Verkauf · Πωλήσεις · Sales · Vente · Vendita · Verkoop · Venda · Myynti · Försäljning 
BELGIQUE/BELGIE IRELAND 
Moniteur belge/ 
Belgisch Staatsblad 
Rue de Louvain 42/Leuvenseweg 42 
B-1000 Bruxelles/B-1000 Brussel 
Tél. (02)512 00 26 
Fax (02) 611 01 84 
Jean De Lannoy 
Avenue bu Roi 202/Koningslaan 202 
B-1060 Bruxelles/B-1060 Brussel 
Tél. (02) 538 51 69 
Fax (02) 538 08 41 
Autres distributeurs/ 
Overige verkooppunten: 
Librairie européenne/ 
Europese boekhandel 
Rue de la Loi 244/Wetstraat 244 
B-1040 BruxeÌìes/B-1040 Brussel 
Tél. (02) 231 04 35 
Fax (02) 735 08 60 
Document delivery: 
Credoc 
Rue de la Montagne 34/Bergstraat 34 
Bolle 11/Bus 11 
B-1000 Bruxelles/B-1000 Brussel 
Tél. (02) 511 69 41 
Fax (02) 513 31 95 
DANMARK 
J. H. Schultz Information A/S 
Herstedvang 10-12 
DK-2620 Albertslund 
Tlf. 43 63 23 00 
Fax (Sales) 43 63 19 69 
Fax (Management) 43 63 19 49 
DEUTSCHLAND 
Bundesanzeiger Verlag 
Postfach 10 OS 34 
D-50445 Köln 
Tel. (02 21)20 29-0 
Fax (02 21) 2 02 92 78 
GREECE/ΕΛΛΑΔΑ 
G.C. Eleftheroudakis SA 
International Bookstore 
Nikis Street 4 
GR-10563 Athens 
Tel. (01)322 63 23 
Fax 323 98 21 
ESPANA 
Mundi­Prensa Libros, SA 
Castelló, 37 
E-28001 Madrid 
Tel. (91)431 33 99 (Libros) 
431 32 22 (Suscripciones) 
435 36 37 (Dirección) 
Fax (91) 575 39 98 
Boletín Oficial del Estado 
Trafalgar, 27-29 
E-28071 Madrid 
Tel. (91)538 22 95 
Fax(91)53B23 49 
Sucursal'. 
Librería Internacional AEDOS 
Consejo de Ciento, 391 
E-08009 Barcelona 
Tel. (93) 488 34 92 
Fax (93) 487 76 59 
Librería de la Generalitat 
de Catalunya 
Rambla deìs Esludis, 118 (PaÌau Moja) 
E-08002 Barcelona 
Tel. (93) 302 68 35 
Tel. (93) 302 64 62 
Fax (93) 302 12 99 
FRANCE 
Journal officiel Service des publications 
des Communautés européennes 
26, rue Desaix 
F-75727 Paris Cedex 15 
Tél. (1) 40 58 77 01/31 
Fax (1)40 58 77 00 
Government Supplies Agency 
4-5 Harcourt Road 
Dublin 2 
Tel. (1)66 13 111 
Fax (1)47 52 760 
ISRAEL 
ITALIA 
Licosa SpA 
Via Duca di Calabria 1/1 
Casella postale 552 
1-50125 Firenze 
Tel. (055) 64 54 15 
Fax 64 12 57 
GRAND-DUCHE DE LUXEMBOURG 
Messageries du livre 
5, rue Raiffeisen 
L-2411 Luxembourg 
Tél. 40 10 20 
Fax 49 06 61 
NEDERLAND 
SDU Servicecentrum Uitgeverijen 
Postbus 20014 
2500 EA 's-Gravenhage 
Tel. (070) 37 89 880 
Fax (070) 37 89 783 
OSTERREICH 
Manz'sche Vertags­
und Universitätsbuchhandlung 
Kohlmarkl 16 
A-1014 Wien 
Tel. (1)531 610 
Fax (1)531 61-181 
Document delivery: 
Wirtschaftskammer 
Wiedner Hauptstraße 
A-1045 Wien 
Tel.(0222)50105-4356 
Fax (0222) 50206-297 
PORTUGAL 
Imprensa Nacional — Casa da Moeda, EP 
Rua Marquês Sá da Bandeira, 16-A 
P-1099 Lisboa Codex 
Tel. (01)353 03 99 
Fax (01) 353 02 94/384 01 32 
Distribuidora de Livros 
Bertrand, Ld.' 
Grupo Bertrand, SA 
Rua das Terras dos Vales, 4-A 
Apartado 37 
P-2700 Amadora Codex 
Tel. (01)49 59 050 
Fax 49 60 255 
SUOMI/FINLAND 
Akateeminen Kirjakauppa 
Akademiska Bokhandeln 
Pohjoisesplanadi 39 / Norra esplanaden 39 
PL /PB 128 
FIN-00101 Helsinki / Helsingfors 
Tel. (90) 121 4322 
Fax (90) 121 44 35 
SVERIGE 
BTJAB 
Traktorvägen 11 
Box 200 
S-221 00 Lund 
Tel. (046) 18 00 00 
Fax (046) 18 01 25 
UNITED KINGDOM 
HMSO Books (Agency section) 
HMSO Publications Centre 
51 Nine Elms Lane 
London SWS 5DR 
Tel. (0171)873 9090 
Fax (0171) 873 8463 
ICELAND 
BOKABUD 
LARUSAR BLÕNDAL 
Skólavorduslíg, 2 
IS­101 Reykjavik 
Tel. 551 56 50 
Fax 552 55 60 
NIC Info a/s 
Boks 6512 Etterstad 
0606 Oslo 
Tel. (22) 57 33 34 
Fax (22) 68 19 01 
SCHWEIZ/SUISSE/SVIZZERA 
OS EC 
Stamptenbachstraße 85 
CH-8035 Zürich 
Tel. (01)365 54 49 
Fax (01) 365 54 11 
BALGARIJA 
Europress Klassica BK Ltd 
66, bd Vitosha 
BG-1463 Sofia 
Tel./Fax (2) 52 74 75 
CESKÁ REPUBLIKA 
NIS ČR 
Havelkova 22 
CZ-130 00Praha3 
Tel./Fax (2) 24 22 94 33 
HRVATSKA 
Mediatrade 
P. Hatza 1 
HR-4100 Zagreb 
Tel./Fax (041) 43 03 92 
MAGYARORSZÁG 
Euro­Info­Service 
Europa Haz 
Margitsziget 
H-1138 Budapest 
Tel./Fax(1) 111 60 61,(1) 111 62 16 
POLSKA 
Business Foundation 
ul. Krucza 38/42 
PL-00-512 Warszawa 
Tel. (2) 621 99 93, 628 28 82 
International Fax&Phone (0-39) 12 00 77 
ROMÃNIA 
Euromedia 
65, Strada Dionisie Lupu 
RO-70184 Bucuresti 
Tel./Fax 1-31 29 646 
RUSSIA 
CCEC 
9,60-letiya Oktyabrya Avenue 
117312 Moscow 
Tel/Fax (095) 135 52 27 
SLOVAKIA 
Slovak Technical 
Library 
Nàm. slobody 19 
SLO-812 23 Bratislava 1 
Tel. (7) 52 204 52 
Fax (7) 52 957 85 
CYPRUS 
Cyprus Chamber of Commerce 
and Industry 
Chamber Building 
38 Grivas Dhigenis Ave 
3 Deligiorgis Street 
PO Box 1455 
Nicosia 
Tel. (2)44 95 00,46 23 12 
Fax (2) 36 10 44 
MALTA 
Miller Distributors Ltd 
PO Box 25 
Malta International Airport LOA 05 Malla 
Tel. 66 44 88 
Fax 67 67 99 
TURKIYE 
Pres AS 
Dünya Infoisi 
TR-80050 Tünel-lstanbul 
Tel. (1)251 91 90/251 96 96 
Fax (1)251 91 97 
Roy International 
17, Shimon Hatarssi Street 
P.O.B 13056 
61130 Tel Avıv 
Tel. (3)546 14 23 
Fax (3) 546 14 42 
Sub-agent lor the Palestinian Authority: 
INDEX Information Services 
PO Box 19502 
Jerusalem 
Tel. (2)27 16 34 
Fax (2) 27 12 19 
EGYPT/ 
MIDDLE EAST 
Middle East Observer 
41 Sherif St. 
Cairo 
Tel/Fax (2) 393 97 32 
UNITED STATES OF AMERICA/ 
CANADA 
UNIPUB 
4611 -F Assembly Drive 
Unham, MD 20706-4391 
Tel. Toll Free (800) 274 48 88 
Fax (301) 459 00 56 
CANADA 
Subscriptions only 
Uniquement abonnements 
Renouf Publishing Co. Ltd 
1294 Algoma Road 
Ottawa, Ontario K1B 3W8 
Tel (613)741 43 33 
Fax (613) 741 54 39 
AUSTRALIA 
Hunter Publications 
58A Gipps Street 
Collingwood 
Victoria 3066 
Tel. (3)9417 53 61 
Fax (3) 9419 71 54 
JAPAN 
Procurement Services Int. (PSI­Japan) 
Kyoku Dome Postal Code 102 
Tokyo Kojimachi Post Office 
Tel. (03) 32 34 69 21 
Fax (03) 32 34 69 15 
Sub-agent: 
Kinokuniya Company Ltd 
Journal Department 
PO Box 55 Chitóse 
Tokyo 156 
Tel. (03)34 39-0124 
SOUTH and EAST ASIA 
Legal Library Services Ltd 
Orchard 
PO Box 0523 
Singapore 9123 
Tel. 243 24 98 
Fax 243 24 79 
SOUTH AFRICA 
Sarto 
5th Floor, Export House 
Cnr Maude & West Streets 
Sandton 2146 
Tel.(011)883-3737 
Fax (011)883-6569 
ANDERE LANDER 
OTHER COUNTRIES 
AUTRES PAYS 
Office des publications officielles 
des Communautés européennes 
2, rue Mercier 
L-2985 Luxembourg 
Tél. 29 29-1 
Télex PUBOF LU 1324 b 
Fax 48 85 73, 48 68 17 
NOTICE TO THE READER 
Ail scientific and technical reports published by the European Commission are announced 
in the monthly periodical 'euro abstracts'. For subscription (1 year: ECU 60) please write 
to the address below. 
Ol 
O 
O 
σ> οι cp 
m 
ζ 
ι 
ο 
Price (excluding VAT) in Luxembourg: ECU 13.50 ISBN =IS-flB7-5S3b-i4 
* * * OFFICE FOR OFFICIAL PUBLICATIONS * jay * OF THE EUROPEAN COMMUNITIES 
* * * L-2985 Luxembourg 
